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ABSTRACT	  
Proteomics	   aims	   to	   link	   genes	   to	   protein	   expression	   and	   function.	   Proteomics	   is	   a	   very	  versatile	   and	   technology-­‐dependent	   discipline	   and	   the	   development	   of	  mass	   spectrometry-­‐based	   proteomics	   has	   advanced	   the	   understanding	   of	   the	   complex	   and	   dynamic	   nature	   of	  proteomes.	   Proteomics	   does	   not	   have	   a	   “one-­‐size-­‐fits-­‐all”	   strategy	   to	   answer	   all	   biological	  questions.	  New	  technical	  approaches	  are	  needed	  to	  overcome	  the	  hurdles,	  e.g.	  issues	  related	  to	   complexity	   and	   dynamic	   ranges	   of	   the	   samples,	   high	   throughput	   and	   post-­‐translational	  modifications,	  in	  the	  field	  of	  proteomics.	  Due	  to	  recent	  technological	  development,	  proteomics	  has	   become	   complementary	   to	   genomics	   and	   transcriptomics	   in	   systems	   biology	   and	   can	  provide	  unique	  contributions.	  In	   this	   thesis	   a	   novel	   microfluidic	   compact	   disc	   based	   system	   was	   tested	   in	   use	   of	   high	  throughput	   sample	   preparation	   of	   digested	   peptide	   samples	   prior	   to	   matrix	   assisted	   laser	  desorption/ionization	   mass	   spectrometry	   (Paper	   I).	   A	   novel	   microfluidic	   electrocapture	  technology	  able	  to	  immobilize	  charged	  biomolecules	  in	  an	  electric	  field	  along	  a	  hydrodynamic	  flow	   was	   further	   developed	   to	   establish	   its	   ability	   to	   separate	   peptides	   of	   protein	   digests	  (Paper	   III).	   The	   same	   technology	   was	   later	   also	   used	   in	   analysis	   of	   glomerular	   membrane	  proteins	   as	   a	   part	   of	   a	   two-­‐dimensional	   fractionation	   system	   in	   combination	   with	   liquid	  chromatography	  mass	  spectrometry	  (Paper	  IV).	  The	   kidney	   glomerulus	   functions	   as	   a	   specialized	   blood	   filter	   unit	   that	   forms	   the	   primary	  urine.	  The	  filtration	  barrier	  is	  composed	  of	  a	  three-­‐layer	  barrier,	  which	  consists	  of	  endothelial	  cells,	  the	  glomerular	  basement	  membrane	  and	  the	  slit	  diaphragm	  between	  epithelial	  podocyte	  foot	  processes.	  The	  glomeruli	  are	  sensitive	   to	  damage	  and	  glomerular	  diseases	  underlie	   the	  majority	   of	   diseases	   leading	   to	   chronic	   kidney	   disease	   and	   renal	   failure.	   Even	   though	   the	  molecular	   composition	   of	   the	   glomerulus	   is	   quite	   well	   known,	   the	   pathomechanisms	   of	  glomerular	   diseases	   are	   still	   poorly	   unknown.	   The	   mouse	   glomerular	   proteome	   was	   now	  studied	   with	   two-­‐dimensional	   gel	   electrophoresis	   in	   combination	   with	   mass	   spectrometry	  (Paper	   II).	   	   Finally	   a	   meta-­‐analysis	   of	   currently	   available	   proteomic	   and	   transcriptomic	  glomerular	   expression	   data	   in	   normal	   and	   disease	   states	   was	   performed	   to	   explore	   the	  usability	   of	   expression	   profiling	   in	   the	   diagnosis,	   prognosis	   and	   prediction	   of	   glomerular	  diseases	  (Paper	  V).	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INTRODUCTION:	  REVIEW	  OF	  LITERATURE	  
Proteomics	  Marc	   Wilkins	   was	   the	   first	   to	   describe	   the	   term	   proteome	   as	   the	   entire	   complement	   of	  proteins	   expressed	   by	   a	   genome	   in	   a	   limited	   entity1.	   Proteomics	   refers	   to	   complex-­‐scale	  studies	  of	  protein	  systems,	  particularly	  the	  protein	  content	  of	  cells,	  tissues	  and	  organs,	  as	  well	  as	  their	  structures	  and	  functions.	  Proteins	  are	  vital	  parts	  of	  living	  organisms,	  as	  they	  are	  the	  main	   components	   of	   the	   physiological	   pathways	   of	   cells	   and	   biological	   structures2.	  Proteomics	   is	   instrumental	   in	   the	   discovery	   of	   biomarkers,	   which	   can	   have	   significance	   in	  diagnosis	  and	  prognosis	  of	  a	  disease,	  as	  well	  as	  monitoring	  the	  efficacy	  of	  a	  therapy3,4.	  	  The	   study	   of	   the	   proteome	   i.e.	   proteomics,	   differs	   from	   protein	   analysis	   in	   that	   it	   is	   the	  characterization	   of	   the	   complete	   repertoire	   of	   individual	   protein	   species	   that	   comprise	   the	  proteome	  rather	  than	  focusing	  on	  a	  single	  protein.	  Proteomics	  aims	  to	  identify	  not	  only	  all	  the	  proteins	  in	  any	  given	  cell	  or	  tissue,	  but	  also	  the	  set	  of	  all	  protein	  isoforms	  and	  modifications,	  the	  interactions	  between	  them,	  the	  structural	  description	  of	  proteins	  and	  their	  higher-­‐order	  complexes,	  and	  for	  that	  matter	  almost	  everything	  post-­‐genomic1.	  The	  development	  of	  mass	  spectrometry	  (MS)	  has	  been	  the	  most	  critical	  for	  the	  rapid	  advance	  of	  proteomics.	  Together	  with	  fractionation	  methods,	  they	  provide	  the	  technology	  to	  measure	  and	  identify	  peptides	  and	  proteins	  in	  large	  scale	  with	  high	  sensitivity5-­‐7.	  Proteomics	  is	  more	  complicated	   than	   genomics,	  mostly	   because	   the	   proteome	   consists	   of	   tens	   of	   thousands	   of	  proteins,	  the	  concentrations	  of	  which	  differ	  from	  cell	  to	  cell,	  while	  the	  genome	  is	  the	  same	  in	  all	   cells.	   Furthermore,	   the	   proteome	   constantly	   changes	   through	   post-­‐translational	  modifications	   (PTMs)	   and	   biochemical	   interactions	   of	   proteins	   with	   other	   proteins,	   the	  genome	   and	   the	   environment8,9.	   Proteomic	   analyses	   are	   important	   because	   they	   provide	   a	  much	   more	   complete	   understanding	   of	   an	   organism	   than	   genomics.	   Proteomics	   is	   today	  considered	   an	   integral	   part	   of	   biological	   research	   together	   with	   genomics	   and	  transcriptomics.	   Proteomics	   provides	   a	   functional	   link	   between	   expressed	   genes	   and	  phenotypic	  outcomes.	  Proteomics	   is	   a	   difficult	   field	   and	   still	   encounters	   many	   problems	   in	   comparison	   with	  genomics	  and	  transcriptomics.	  The	  number	  of	  genes	  in	  a	  cell	  is	  constant	  in	  comparison	  with	  the	  proteins.	  The	  proteome	  is	  not	  a	  predetermined	  static	  entity.	  It	  is	  in	  constant	  flux,	  which	  is	  influenced	   by	   environmental	   conditions,	   cellular	   function,	   developmental	   status	   and	  
	  	   	  	  	   	  	  2	  
extracellular	   challenge.	   Even	   when	   a	   cell	   is	   in	   steady	   state,	   the	   protein	   complement	   is	  constantly	  changing,	  with	  new	  proteins	  being	  synthesized	  and	  older	  proteins	  being	  degraded	  and	  recycled	  in	  a	  way	  that	  does	  not	  harm	  the	  cellular	  equilibrium10.	  DNA	  and	  mRNA	  can	  be	  amplified	   easily	   using	   specific	   methods.	   Studying	   mRNA	   has	   its	   advantages.	   Reverse	  transcriptase	   polymerase	   chain	   reaction	   (RT-­‐PCR)	   can	   be	   used	   to	   amplify	   mRNA.	   For	  qualitative	   analysis	   real-­‐time	   RT-­‐PCR	   is	   used.	   Detection	   and	   analysis	   of	   mRNAs	   are	   quite	  straightforward	  with	   the	  use	  of	  hybridization	  techniques.	  However	   the	   levels	  of	  mRNA	   in	  a	  cell	   do	   not	   always	   reflect	   the	   levels	   of	   corresponding	   proteins11-­‐13.	   Furthermore,	   studying	  only	  mRNA	  levels	  cannot	  validate	  PTMs	  and	  functional	  analysis	  of	  proteins.	  Proteins	   are	   a	   group	   of	   heterogeneous	   molecules	   with	   variable	   properties	   in	   weight,	  hydrophobicity	  and	  charge.	  The	  analysis	  of	  a	  full	  proteome	  poses	  inevitable	  challenges	  due	  to	  the	   limitation	   and	   variability	   of	   sample	   material,	   post-­‐translational	   modifications,	   splice	  variants,	   sample	   stability	   and	   degradation,	   variety	   of	   their	   dynamic	   range,	   transient	   protein	  associations	  and	  dependence	  on	  cell	  type	  or	  physiological	  state.	  Success	  in	  a	  proteomic	  study	  is	  enabled	   and	   confined	   by	   the	   biological	   system,	   the	   study	   plan,	   available	   technology.	   To	  overcome	   these	   significant	   challenges	   in	   proteomics,	   new	   analytical	   strategies	   have	   been	  developed	   in	   which	   mass	   spectrometry	   (MS)	   is	   the	   central	   element	   with	   increased	  performance	  and	  versatility	  of	  the	  instrumentation14,15.	  	  	  
Mass	  spectrometry	  Mass	   spectrometry	   (MS)	   is	   a	   well-­‐known	   analytical	   tool	   for	   the	   measurement	   of	   molecular	  weight	   of	   a	   sample	   or	   distinguishing	   molecules	   by	   their	   mass-­‐to-­‐charge	   ratios.	   Mass	  spectrometers	   are	   now	   routinely	   used	   in	   both	   industry	   and	   academia	   for	   various	   purposes	  such	   as	   drug	   discovery,	   diagnostics	   and	   bio-­‐analyses.	   A	   mass	   spectrometer	   is	   an	   analytical	  device	  that	  determines	  the	  molecular	  weight	  of	  chemical	  compounds	  by	  separating	  molecular	  ions	   in	  a	  gas	  phase	  according	   to	  mass-­‐to-­‐charge	   ratio	   (m/z).	  Mass	   spectrometers	  have	   three	  basic	  components:	  an	  ion	  source,	  a	  mass	  analyzer	  and	  a	  detector.	  In	  the	  ion	  source,	  the	  ions	  are	  transferred	  into	  the	  gas	  phase	  as	  positive	  or	  negative	  ions	  and	  accelerated	  in	  an	  electric	  field.	  The	  m/z	  of	  the	  ions	  is	  determined	  in	  the	  mass	  analyzer.	  The	  detector	  registers	  the	  amount	  of	  ions	  at	  each	  m/z	  value.	  	  An	  optional	  pre-­‐fractionation	  part	  is	  sometimes	  coupled	  for	  enhanced	  performance.	  In	  schemes	  for	  tandem	  MS	  analysis,	  dual	  mass	  analyzers,	  that	  are	  separated	  by	  a	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collision	  cell	   for	   fragmentation	  of	   target	  molecules,	  are	  usually	  employed,	   (Figure	  1).	  Matrix-­‐assisted	   laser	   desorption	   ionization	   (MALDI)16,17	   and	   Electrospray	   ionization	   (ESI)18	   are	   the	  most	   common	   ionization	   techniques.	   The	   developers	   of	   these	   two	   techniques	   received	   the	  Nobel	   Prize	   in	   chemistry	   2002.	   	   MALDI	   and	   ESI	   are	   so	   called	   soft	   ionization	   techniques	  meaning	  they	  are	  compatible	  with	  large	  and	  fragile	  biomolecules.	  	  	  
	  
Figure	  1.	  	  A	  simplified	  workflow	  for	  a	  mass	  spectrometry	  (MS)	  analysis	  in	  proteomics.	  A	  protein/peptide	  sample	   can	   be	   analyzed	   directly	   with	   MS	   if	   the	   sample	   is	   relative	   simple.	   For	   more	   complex	   samples,	  prefractionation	  methods	  can	  be	  added	   to	   increase	   the	  number	  of	   identification.	  Depending	  on	   the	  method	  of	  choice,	  the	  masses	  or	  the	  sequences	  of	  the	  peptides	  can	  be	  analyzed.	  	  	  In	  the	  beginning	  of	  the	  21st	  century,	  mass	  spectrometry	  was	  used	  in	  three	  major	  fields.	  It	  was	  used	   to	   identify	   proteins	   and	  biomolecules.	   It	  was	   also	   the	  method	  of	   choice	   to	  detect	   and	  characterize	   post-­‐translational	   modifications.	   Finally,	   it	   was	   the	   preferred	   technique	   for	  characterization	   and	   quality	   control	   of	   recombinant	   proteins	   and	  macromolecules	   in	   both	  academia	   and	   biotechnological	   industry19.	   Since	   then,	   driven	   by	   the	   need	   to	   identify,	  characterize,	  and	  quantify	  proteins	  at	  ever	   increasing	  sensitivity	  and	   in	  ever	  more	  complex	  samples,	   a	  wide	  range	  of	  MS-­‐based	  analytical	  approaches	  and	  experimental	   strategies	  have	  emerged.	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The	   idea	   of	   shotgun	   proteomics	   evolved	   from	   the	   fact	   that	   the	   new	   large-­‐scale	   analysis	  methods	  were	  needed	  to	  overcome	  the	  disadvantages	  of	  2-­‐DE.	  The	  term	  shotgun	  proteomics	  involves	   the	   analysis	   of	   a	   complex	   mixture	   of	   proteins	   digested	   into	   peptides,	   which	   are	  separated	  by	  at	  least	  a	  two-­‐dimensional	  chromatography	  based	  separation	  system	  and	  eluted	  directly	  into	  a	  tandem	  mass	  spectrometer	  in	  an	  automated	  fashion.	  The	  data	  are	  analyzed	  by	  powerful	  computational	  systems20-­‐22.	   	   It	   is	  also	  possible	  to	  do	  quantitative	  and	  comparative	  pattern	  analyses	  with	  mass	  spectrometry23.	  	  
Ionization	  techniques	  
Matrix-­‐assisted	  laser	  desorption	  ionization	  (MALDI)	  Matrix-­‐assisted	   laser	   desorption	   ionization	   (MALDI)	   was	   developed	   at	   the	   end	   of	   the	  1980s16,17	  and	  is	  today	  widely	  used	  in	  mass	  spectrometers.	  MALDI	  ionization	  is	  based	  on	  the	  utilization	  of	  a	  crystalline	  matrix,	  which	  is	  able	  to	  absorb	  the	  energy	  of	  a	  pulsed	  laser	  beam	  and	   to	  mediate	   the	   generation	  of	   peptide	   ions.	   Small	   organic	  molecules	   such	  as	  α-­‐cyano-­‐4-­‐hydroxy-­‐cinnamic	   acid	   and	   3,5-­‐methoxy-­‐4-­‐hydroxy-­‐cinnamic	   acid	   are	   commonly	   used	  matrices.	   MALDI	   is	   compatible	   with	   relatively	   simple	   peptide	   mixtures,	   proteins	   or	   lipids.	  Advantages	  with	  MALDI	  are	  that	  it	  is	  sensitive	  and	  can	  tolerate	  high	  concentrates	  of	  salts	  and	  other	  impurities.	  MALDI	  instruments	  are	  also	  robust	  and	  easy	  to	  use	  at	  low	  cost.	  MALDI	  can	  further	   be	   used	   for	   in	   situ	   profiling	   and	   imaging	   of	   proteins	   in	   tissues24.	  MALDI	   is	   usually	  coupled	  to	  a	  time-­‐of-­‐flight	  (TOF)	  analyzer.	  MALDI-­‐TOF	  instruments	  (Figure	  2)	  have	  become	  an	  analytical	  technique	  in	  proteomics	  for	  the	  identification	  of	  proteins	  separated	  by	  2-­‐DE	  25,26.	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analyzer.	  A	  general	  principle	   is	  that	  smaller	   ions	  will	  reach	  the	  detector	  first.	  A	  reflectron	  in	  the	  TOF-­‐analyzer	  increases	  the	  resolution	  of	  the	  mass	  spectrometer.	  	  
	  
Electrospray	  ionization	  (ESI)	  Electrospray	  ionization	  (ESI)	  (Figure	  3)	  is	  the	  most	  widely	  used	  technique	  for	  the	  analysis	  of	  samples	   in	   liquid	   form27.	   Because	   it	   ionizes	  molecules	   directly	   from	   the	   liquid	   phase,	   it	   is	  compatible	  with	  traditional	  chromatographic	  separation	  techniques	  widely	  used	  in	  analytical	  chemistry.	  Ions	  released	  by	  electrospray	  are	  very	  stable.	  The	  ionization	  process	  is	  unlimited	  in	  mass28.	  These	  characteristics,	  paired	  with	  its	  very	  high	  ionization	  efficiency,	  are	  the	  basis	  for	  the	  wide	  use	  of	  electrospray	  ion	  sources29.	  	  Electrospray	  is	  an	  atmospheric	  ionization	  method	  that	  produces	  small	  charged	  droplets	  from	  the	   liquid	  medium	  under	  the	   influence	  of	  an	  electric	   field.	   In	  a	  usual	  electrospray,	  a	   flow	  of	  liquid	   is	   passed	   through	   a	   thin	   conducting	   capillary	   needle	   at	   high	   electric	   voltage.	   The	  potential	   difference	   is	   applied	   between	   the	   needle	   and	   the	   counter	   electrode.	   The	   analytes	  exist	   as	   ions	   in	   the	   liquid	   phase	   and	   the	   applied	   potential	   will	   create	   an	   accumulation	   of	  charged	  ions	  at	  the	  tip	  of	  the	  needle.	  Either	  the	  positive	  or	  the	  negative	   ions	  migrate	  to	  the	  end	  of	   the	   capillary,	  depending	  on	  polarity	  of	   the	  applied	  electric	   field.	  The	  high	  density	  of	  positively	  charged	   ions	  at	   the	  tip	   leads	  to	  the	   formation	  of	  a	  Taylor	  cone30	  due	  to	  repulsive	  forces	  between	   the	  positive	   ions.	  Under	   a	   sufficiently	  high	   electric	   field,	   the	   forces	  become	  stronger	  than	  the	  surface	  tension	  at	  the	  tip	  of	  the	  cone	  and	  a	  liquid	  mist	  is	  ejected.	  The	  mists	  break	   up	   in	   small	   highly	   charged	   droplets	   when	   moving	   towards	   the	   counter	   electrode31.	  Both	  a	  potential	  and	  a	  pressure	  gradient	  will	  direct	  the	  droplets	  towards	  the	  inlet	  of	  the	  mass	  spectrometer	   and	   a	   counter	   current	   gas	   flow	   facilitates	   solvent	   vaporization	   and	   prevents	  further	  ion	  cluster	  formation.	  As	  the	  solvent	  continues	  to	  evaporate,	  the	  size	  of	  the	  droplets	  will	   decrease	   until	   they	   reach	   a	   diameter-­‐size	   in	   the	   nanometer	   range32,33.	   ESI	   mass	  spectrometers	   are	   coupled	   with	   different	   sets	   of	   quadrupole	   (Q)	   and	   time-­‐of-­‐flight	   (TOF)	  mass	  analyzers.	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Figure	  3.	  Representation	  of	  the	  electrospray	  ionization	  (ESI)	  process.	  A	  positive	  potential	  is	  applied	  to	  the	  capillary	  needle,	  causing	  positive	  ions	  in	  the	  solution	  to	  migrate	  towards	  the	  tip	  of	  the	  droplet	  and	  negative	  ions	  tend	  to	  move	  toward	  the	  wall	  of	  the	  needle.	  Destabilization	  of	  the	  meniscus	  leads	  to	  the	  formation	  of	  a	  Taylor	  cone	  emitting	  positively	  charged	  droplets	  into	  the	  atmosphere.	  Gas-­‐phase	  ions	  are	  formed	  from	  the	  droplets	  as	  the	  solvent	  evaporates	  when	  they	  are	  accelerated	  towards	  the	  entrance	  of	  the	  mass	  spectrometer.	  	  
Mass	  analyzers	  Mass	  analyzers	  separate	  the	  ions	  according	  to	  the	  m/z	  ratios.	  There	  are	  many	  types	  of	  mass	  analyzers,	  time-­‐of-­‐flight	  (TOF),	  quadrupole	  (Q),	  many	  types	  of	  ion	  traps	  and	  fourier	  transform	  ion	  cyclotron	  resonance	  (FTICR)	  devices,	  which	  can	  be	  coupled	  together	  in	  different	  manners	  with	   MALDI	   or	   ESI	   sources	   to	   influence	   the	   sensitivity,	   mass	   accuracy,	   mass	   range	   and	  resolution	  of	  the	  instrument.	  Only	  TOF	  and	  Q	  analyzers	  are	  discussed	  here.	  	  	  
Time-­‐of-­‐flight	  (TOF)	  analyzer	  The	  TOF	  analyzers	  are	  usually	  interfaced	  with	  MALDI	  to	  perform	  pulsed	  analysis	  of	  individual	  samples.	  The	  analyzer	  measures	  the	  time	  of	  flight	  of	  the	  ions	  across	  the	  tube	  to	  the	  detector.	  The	  ions	  will	  be	  separated	  in	  the	  analyzer	  according	  to	  their	  m/z	  ratios,	  thus	  light	  ions	  will	  fly	  faster	   than	   heavy	   ions	   when	   they	   carry	   the	   same	   number	   of	   charges.	   	   To	   increase	   the	  resolution	   of	   the	   TOF	   analyzer	   a	   reflectron	  was	   introduced	   in	   197334.	   The	   reflectron	   is	   an	  electrostatic	  device	  inside	  the	  TOF	  tube,	  which	  reflects	  the	  ions	  180	  degrees	  from	  the	  original	  direction.	  	  The	  reflectron	  is	  used	  to	  compensate	  the	  differences	  of	  kinetic	  energy	  of	  same	  m/z	  ions.	  The	  reflectron	  serves	  to	  increase	  the	  amount	  of	  time	  (t)	  ions	  need	  to	  reach	  the	  detector	  while	  reducing	  the	  differences	  of	  kinetic	  energy	  of	  the	  same	  m/z	  ions,	  thereby	  reducing	  the	  temporal	   distribution	   Δt.	   Since	   resolution	   is	   defined	   by	   the	  mass	   of	   a	   peak	   divided	   by	   the	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width	   of	   a	   peak	   or	  m/Δm	   (or	   t/Δt	   since	  m	   is	   related	   to	   t),	   increasing	   t	   and	   decreasing	   Δt	  results	  in	  higher	  resolution.	  (Figure	  2).	  	  
Quadrupole	  (Q)	  analyzer	  A	  quadrupole	  mass	  analyzer35	  contains	  four	  rods	  that	  work	  in	  pairs.	  Each	  pair	  is	  connected	  to	  a	  direct	  current	  (DC)	  voltage	  with	  a	  superimposed	  oscillating	  radio	  frequency	  (RF).	  One	  pair	  has	   a	   positive	   voltage	  while	   the	   other	   pair	   is	   negatively	   charged	   at	   a	   time.	   Specific	   DC/RF	  ratios	  let	  ions	  of	  certain	  m/z	  ratios	  through.	  Too	  low	  m/z	  values	  make	  the	  ions	  oscillate	  in	  the	  RF	  field	  with	  increasing	  amplitude	  until	  they	  hit	  a	  rod	  and	  are	  discharged.	  Ions	  with	  too	  high	  m/z	  values	  will	  also	  hit	  the	  rods	  and	  will	  be	  discharged.	  By	  varying	  the	  DC/RF	  ratio,	  the	  mass	  analyzer	  thus	  scans	  an	  m/z	  interval.	  By	  locking	  the	  DC/RF	  ratio	  only	  ions	  with	  a	  limited	  m/z	  value	  may	  pass	  the	  analyzer.	  	  An	  important	  feature	  of	  the	  quadrupole	  is	  that	  it	  stably	  guides	  and	  focuses	   ions,	  making	  them	  suitable	  for	  operation	  as	  an	  ion	  transmission	  guide	  and	  as	  a	  collision	  cell.	  This	  makes	  the	  quadrupoles	  excellent	  mass	  filters	  and	  the	  technique	  is	  used	  in	  tandem	   mass	   spectrometry.	   Quadrupoles	   are	   today	   used	   in	   many	   different	   setups	   and	  combinations	  of	  analyzers	  in	  mass	  spectrometers.	  	  	  
Clinical	  proteomics	  and	  mass	  spectrometry	  Proteomics	  has	  an	  important	  role	  in	  clinical	  research.	  To	  understand	  what	  is	  really	  occurring	  in	   cells,	   tissues	   or	   organs	   in	   disease	   states,	   it	  would	   be	   important	   to	   study	   the	   expression	  profiles	  of	  proteins,	  because	  they	  are	  the	  functional	  units	  and	  regulators	  of	  cells	  and	  organs.	  Mass	   spectrometry	   has	   gradually	   become	   the	   primary	   choice	   of	   tool	   in	   clinical	   proteomics	  research.	  Mass	  spectrometers	  are	  sensitive	  (femto-­‐	  or	  attomole	  sensitivity)36	  and	  can	  handle	  complex	   peptide	   mixtures.	   Mass	   spectrometers	   can	   be	   coupled	   online	   with	   various	   liquid	  phase	   prefractionation	   methods	   to	   reduce	   the	   sample	   loss	   and	   increase	   the	   rate	   of	  identification	  of	  proteins.	  MS-­‐based	  proteomics	  has	  been	  used	  to	  identify	  and	  quantify	  almost	  the	  whole	  yeast	  proteome	  in	  a	  single	  run37,38.	  This	  same	  approach	  can	  be	  used	  with	  clinical	  samples.	   MS	   can	   identify	   peptides	   and	   proteins	   in	   normal	   cells	   or	   tissues,	   and	   do	   relative	  comparisons	  of	  protein	  expression	  with	  disease	  states	  using	  tags.	  In	  this	  manner	  it	  is	  possible	  to	   see	   the	   expression	   levels	   of	   proteins,	   what	   cell	   functions	   they	   represent,	   and	   which	  signaling	   pathways	   that	   are	   affected	   in	   diseases.	   	   It	   is	   possible	   to	   study	   post-­‐translational	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modifications	   in	   disease	   states	   and	   get	   knowledge	   about	   activation,	   deactivation	   or	   re-­‐localization	   of	   proteins	   and	   how	   PTMs	   regulate	   biological	   functions	   and	   processes.	  Proteomics	   has	   now	   been	   accepted	   as	   an	   important	   part	   of	   systems	   biology.	   Studies	   on	  proteomic	   expression	   profiles	   and	   pathways	   might	   contribute	   to	   detection	   of	   novel	   drug	  targets	   or	   biomarkers,	   and	   may	   also	   explain	   why	   some	   patients	   react	   to	   some	   treatment	  while	  others	  do	  not.	  	  
Sample	  preparation	  techniques	  Proper	   sample	   preparation	   is	   crucial	   in	   proteomics.	   Out	   of	   the	   genome	   of	   approximately	  20,500	  genes,	  tissue	  cells	  may	  express	  more	  than	  10,000	  genes	  and	  therefore	  the	  number	  of	  proteins	  expressed	  in	  cells	  and	  tissues	  is	  very	  large.	  The	  dynamic	  range	  is	  the	  ratio	  between	  the	  concentration	  of	  the	  least	  abundant	  and	  the	  most	  abundant	  protein	  in	  a	  complex	  mixture.	  The	  dynamic	  range	  of	  plasma	  has	  been	  measured	  to	  be	  more	  than	  10	  orders	  of	  magnitude	  in	  concentration	  difference	  between	  albumin	  and	  the	  rarest	  proteins	  clinically	  detected39.	  Two-­‐dimensional	   gels	   can	   separate	   roughly	   up	   to	   2,000	   protein	   spots.	   It	   is	   usually	   the	   high	  abundant	  proteins	  that	  will	  be	  visualized	  in	  a	  crude	  sample.	  Large,	  hydrophobic	  and	  alkaline	  proteins	  (with	  pI	  >10)	  are	  difficult	  to	  detect.	  To	  be	  able	  to	  detect	   low	  abundant	  proteins	  an	  appropriate	  sample	  preparation	  method	  has	  to	  be	  used40-­‐42.	  	  Several	  properties	  of	  the	  sample	  have	  to	  be	  taken	  into	  account	  before	  it	  can	  be	  prepared.	  First	  the	  biological	  origin	  of	   the	   sample	  has	  a	   significant	   role	   in	  how	   to	  process	   the	   sample.	  Cell	  culture	   and	   cell	   component	   studies	   are	   quite	   straightforward.	   Cell	   cultures	   contain	  homogeneous	   sub-­‐populations	   that	   produce	   much	   material	   for	   further	   analysis.	   Biological	  fluid-­‐samples	   can	   easily	   be	   obtained	   in	   standard	   clinical	   procedures.	   Despite	   this,	   it	   is	  important	  to	  standardize	  the	  whole	  procedure	  for	  sample	  handling	  from	  the	  sampling	  to	  the	  analysis.	   In	   contrast	   to	   cell	   cultures,	   fluid-­‐samples	   are	  often	  non-­‐homogeneous	  mixtures	  of	  different	  cell	  types	  and	  soluble	  proteins	  from	  the	  organism.	  Therefore,	  separation	  of	  cellular	  and	  soluble	  proteins	  is	  often	  required.	  Tissue	  samples	  obtained	  from	  surgery	  are	  challenging	  because	   the	   samples	   usually	   contain	   different	   cell	   types	   and	   blood.	   	   Samples	   need	   to	   be	  handled	  in	  a	  standardized	  and	  correct	  manner	  to	  remove	  the	  impurities	  in	  such	  a	  mode	  that	  the	  proteins	  remain	  intact.	  A	  delay	  in	  sample	  handling	  may	  compromise	  the	  integrity	  of	  the	  sample.	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Depending	   on	   the	   localization,	   solubility,	   activity	   and	   quantity	   of	   a	   protein	   or	   proteins	   of	  interest,	   different	   purification,	   preparation	   and	   analysis	   approaches	   are	   needed,	   because	   a	  certain	  strategy	  for	  one	  set	  of	  proteins	  is	  not	  always	  compatible	  for	  another	  one.	  Samples	  are	  prepared	  differently	  to	  study	  cytosolic	  and	  membrane	  proteins.	  In	  projects	  that	  focus	  on	  the	  expression	   and	   identification	   of	   proteins,	   samples	   are	   treated	   with	   chaotropic	   agents,	  detergents	   and	  protease	   inhibitors	   to	  denature	   and	   inactivate	   the	  proteases.	  When	  protein	  activities	  are	  studied,	  it	  is	  instead	  important	  to	  keep	  the	  proteins	  intact,	  properly	  folded	  and	  as	  active	  as	  possible	  during	  the	  experiment.	  This	  limits	  the	  extraction	  methods	  available	  and	  there	  is	  a	  risk	  for	  continuous	  changes	  in	  the	  integrity	  of	  the	  sample.	  	  To	  be	  able	  to	  study	  low-­‐abundant	   proteins,	   prefractionations	   must	   be	   carried	   out	   using	   chromatographic	   and	  microfluidic	  methods.	  There	   are	   two	   main	   approaches	   to	   separate	   complex	   protein	   samples	   prior	   to	   mass	  spectrometric	   analysis:	   gel-­‐based	   and	   gel-­‐free	   separation	   methods.	   Gel-­‐based	   methods	  include	   one-­‐	   (1-­‐DE)	   and	   two-­‐dimensional	   gel	   electrophoresis	   (2-­‐DE).	   One	   of	   the	   most	  significant	   breakthroughs	   in	   proteomics	   was	   the	   mass	   spectrometric	   compatibility	   of	   gel-­‐separated	   proteins.	   	   Gel-­‐separated	   proteins	   are	   often	   analyzed	   with	   matrix-­‐assisted	   laser	  desorption	  ionization	  mass	  spectrometry	  (MALDI-­‐MS)43.	  In	  this	  approach	  separated	  proteins	  are	   prepared	   manually	   for	   offline	   mass	   spectrometric	   analysis.	   High-­‐pressure	   liquid	  chromatography	  (HPLC)	  and	  other	  liquid	  chromatographic	  methods	  are	  the	  most	  commonly	  used	   gel-­‐free	  methods.	   Coupling	   of	   HPLC	   to	   electrospray	   tandem	  mass	   spectrometry	   (ESI-­‐MS/MS)	  has	  gained	  wide	  acceptance	  for	  gel-­‐free	  proteome	  analysis.	  It	  has	  been	  used	  to	  study	  low	  abundance	  proteins	  and	  membrane	  proteins44,45.	  Compared	  to	  2-­‐DE,	  LC-­‐based	  methods	  are	  more	  efficient	  for	  analysis	  of	  small	  proteins	  and	  peptides	  as	  well	  as	  highly	  hydrophobic	  proteins46.	  A	  new	  technology	  to	  separate	  is	  a	  microfluidic	  electrocapture	  to	  separate	  proteins	  and	   peptides	   according	   to	   electric	   and	   hydrodynamic	   forces	   on	   the	   proteins.	   A	   major	  advantage	  with	  the	  gel-­‐free	  approaches	  is	  that	  protein	  or	  peptide	  samples	  can	  be	  coupled	  on-­‐line	  with	   electrospray	   ionization	  mass	   spectrometry	   (ESI-­‐MS),	   and	   therefore	   avoid	   sample	  loss	  during	  manual	  sample	  handling.	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Two-­‐dimensional	  gel	  electrophoresis	  Sodium	  dodecyl	  sulfate	  polyacrylamide	  gel	  electrophoresis	  (SDS-­‐PAGE)	  is	  a	  well-­‐established	  method	   for	   the	  separation	  of	  proteins	  on	   the	  basis	  of	   the	  molecular	  weights47,48.	   Isoelectric	  focusing	  (IEF)	  is	  used	  to	  separate	  proteins	  according	  to	  their	  charge	  (isoelectric	  point,	  pI	  =	  pH	  at	  which	  the	  net	  charge	  of	  the	  protein/peptide	  is	  zero)49.	  Kenrick	  and	  Margolis	  were	  the	  first	  to	   introduce	  a	  method	  which	  combined	  the	  two	  methods50.	  O’Farrell	  developed	  the	  method	  resulting	  in	  high	  resolution	  2-­‐DE51	  (Figure	  4).	  	  	  
	  
Figure	  4.	  The	  general	  principle	  of	  2-­‐DE.	  Proteins	  are	  separated	  first	  according	  to	  their	  isoelectric	  point	  (pI)	  on	  an	  immobilized	  pH	  gradient	  strip.	  Proteins	  are	  then	  separated	  according	  to	  their	  molecular	  weight	  (Mw).	  As	  a	  result,	  each	  spot	  on	  the	  two-­‐dimensional	  gel	  represents	  one	  protein.	  	  	  2-­‐DE	   is	   a	   powerful	   and	   widely	   used	   method	   for	   separation	   of	   complex	   protein	   mixtures	  extracted	  from	  cells,	   tissues	  or	  other	  biological	  samples.	  The	  proteins	  are	  first	  separated	  by	  IEF	  according	  to	  their	  pIs	  using	   immobilized	  pH	  gradient	  strips	  and	  then	  according	  to	  their	  molecular	   weights	   using	   SDS-­‐PAGE.	   	   After	   the	   2-­‐D	   gel	   electrophoresis,	   the	   proteins	   are	  visualized.	  Ideally	  each	  protein	  spot	  on	  a	  gel	  would	  represent	  an	  individual	  protein.	  Different	  forms	  of	  the	  same	  proteins	  with	  different	  post-­‐translational	  modifications	  are	  also	  separated.	  Gel	   spots	   are	   commonly	   stained	   with	   Coomassie	   brilliant	   blue	   (CBB)	   or	   silver.	   Organic	  solvent-­‐based	   CBB-­‐R	   staining	   has	   a	   limit	   detection	   limit	   in	   the	   order	   of	   0.1	   µg	   while	   the	  
+ - 
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water-­‐based	   CBB-­‐G	   is	   approximately	   four	   times	   more	   sensitive52.	   Silver	   stains	   can	   reach	  down	  to	  approximately	  1	  ng53.	  Silver	  staining	  methods	  have	  developed	  drastically	  during	  the	  past	   decade	   and	   are	   today	   compatible	   with	   mass	   spectrometry54.	   	   Approximately	   2,000	  proteins	  can	  be	  separated	  simultaneously	  with	  a	  single	  2-­‐DE	  and	  information	  of	  the	  pI	  of	  the	  protein,	   the	  apparent	  molecular	  weight,	  post-­‐translational	  modifications	  and	   the	  amount	  of	  proteins	  of	  each	  protein	  can	  be	  obtained55,56.	  	  Two-­‐dimensional	  electrophoresis	  is	  a	  nice	  method	  for	  protein	  separation,	  because	  it	  is	  highly	  reproducible,	  has	  capability	  to	  readily	  visualize	  post-­‐translationally	  modified	  proteins	  as	  they	  tend	   to	   appear	   as	   distinct	   rows	   of	   spots,	   and	   because	   it	   can	   be	   used	   for	   quantitative	  expression	   profiling.	   But	   it	   also	   has	   its	   drawbacks.	   2-­‐DE	   has	   a	   limited	   dynamic	   range	   for	  detection.	   Housekeeping	   proteins	   and	   highly	   abundant	   proteins	   drench	   the	   low-­‐abundant	  proteins	   in	   the	   2-­‐DE55,57,58.	   To	   improve	   the	   detection	   of	   the	   low	   abundant	   proteins,	   crude	  protein	   mixtures	   should	   be	   prefractionated	   to	   study	   the	   sub-­‐proteomes.	   	   Proteins	   can	   be	  fractionated	   according	   to	   their	   chemical	   properties,	   post-­‐translational	   modifications	   and	  subcellular	   location59,60.	   	   Another	   major	   drawback	   of	   2-­‐DE	   is	   the	   poor	   resolution	   of	  membrane	   and	   large	   hydrophobic	   proteins	   since	  most	   of	   them	   are	   not	   soluble	   in	   aqueous	  solution	  and	   thus	  do	  not	  enter	   the	  pH	  strips	  during	   the	   first	  dimension61.	  Other	  drawbacks	  include	   large	   amount	   of	   sample	   handling56,	   difficulty	   to	   identify	   proteins	   with	   high	   pI	  values57,	  high	  molecular	  weight62	  and	  hydrophobic	  properties63.	  	  Typically,	   2-­‐DE	   analysis	   combined	   with	   MALDI-­‐MS	   mass	   fingerprinting	   results	   in	   the	  identification	  of	  300-­‐500	  different	  proteins	  with	  many	  post-­‐translational	  modifications	  and	  isoforms64,65.	   This	   represents	   only	   approximately	   5-­‐10%	   of	   a	   given	   cellular	   and	   organelle	  proteome.	  Therefore,	  sensitive	  liquid	  chromatographic	  separation	  methods	  need	  to	  be	  used,	  additionally,	   to	   explore	   the	   entire	   proteome.	   Despite	   the	   drawbacks,	   2-­‐DE	   is	   still	   a	   very	  widely	   used	   tool	   in	   the	   proteomic	   research	   to	   identify	   novel	   proteins	   and	   especially	   to	   do	  relative	   quantitative	   analyses	   between	   healthy	   and	   disease	   state	   tissue	   samples.	   This	  approach	  is	  e.g.	  extensively	  used	  in	  tumor	  proteomics66. 
 
High	  performance	  liquid	  chromatography High	   performance	   liquid	   chromatography	   (HPLC)	   separates	   biological	   molecules	   based	   on	  their	   unique	   characteristics	   and	   interactions	   with	   the	   stationary	   phase	   of	   the	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chromatography	   column.	   In	   MS-­‐based	   proteomics,	   HPLC	   can	   be	   directly	   coupled	   to	   mass	  spectrometry	   instruments.	   Typically	   reverse	   phase	   (RP),	   ion	   exchange	   (IEX),	   hydrophilic-­‐interaction	  chromatography	  (HILIC)	  and	  affinity	  chromatography	  are	  coupled	  with	  MS67.	  	  Reverse	   phase	   liquid	   chromatography	   (RPLC)	   separates	   peptides	   based	   on	   their	  hydrophobicity.	   It	   is	  probably	   the	  most	  widely	  used	  method	  of	   liquid	  chromatography.	  The	  significant	   advantages	   of	   RPLC	   are	   that	   the	   buffers	   used	   are	   compatible	  with	   electrospray	  ionization	  and	  that	  the	  peptide	  sample	  is	  desalted	  at	  the	  same	  time21,68.	  Given	  high	  resolution,	  efficiency,	   reproducibility,	   and	   mobile	   phase	   compatibility	   with	   ESI,	   the	   analytical	   RPLC	  performs	  the	  final	  separation	  of	  peptides	  prior	  to	  mass	  analysis21.	  The	  use	  of	  longer	  columns	  with	   smaller	  particle	   sizes	   and	  ultra	  high	  pressure	  has	  been	   shown	   to	   further	   improve	   the	  resolution,	  sensitivity	  and	  analysis	  time69-­‐71.	  	  
	  
Microfluidic	  electrocapture	  technology	  Microfluidics	   deals	   with	   the	   behavior,	   control	   and	   manipulation	   of	   fluids	   at	   the	   micro-­‐	   or	  nanoscale.	   It	   involves	   and	   has	   its	   origin	   in	   many	   different	   fields.	   Early	   microanalytical	  methods	   were	   traced	   to	   several	   methods,	   e.g.	   gas	   chromatography	   (GC),	   liquid	  chromatography	   (LC)	   and	   capillary	   electrophoresis	   (CE)72,73.	   Microfluidics	   provides	   a	  multifunctional	   and	   high-­‐throughput	   tool	   for	   the	   analysis	   of	   proteins	   and	   other	  biomolecules74,75.	  Microfluidic	   electrocapture	   (Figure	   5)	   is	   a	   novel	   technique	   introduced	   in	  the	   early	   2000	   that	   is	   used	   in	   the	   analysis	   of	   proteins	   and	   other	   biomolecules	   by	   mass	  spectrometry76.	  It	  involves	  the	  use	  of	  an	  electrocapture	  cell	  integrated	  into	  a	  platform	  with	  a	  syringe	  pump,	  microinjector	  and	  power	  supply	   for	  electroimmobilization	  and	  manipulation	  of	  charged	  molecules.	  The	  technique	  has	  the	  ability	  to	  trap	  charged	  species	  such	  as	  proteins,	  peptides	  and	  DNA	  in	  a	  microfluidic	  chamber	  and	  manipulate	  them	  in	  different	  manners.	  It	  is	  capable	   of	   simultaneously	   performing	   several	   steps	   in	   protein	   analysis	   e.g.	   reduction,	  alkylation,	   digestion,	   concentration,	   cleanup,	   fractionation	   and	   separation	   of	   biological	  samples75,77,78.	   It	   has	   been	   rapidly	   developed	   in	   recent	   years,	   particularly	   in	   terms	   of	   its	  applications	   to	   proteomics,	   consolidating	   the	   advantages	   of	   both	  microfluidic	   and	   sorbent-­‐free	  electric	  field	  gradient	  systems.	  Major	  advantages	  are	  that	  it	  can	  handle	  hydrophilic	  and	  membrane	  proteins	  and	  can	  be	  connected	  on-­‐line	  with	  mass	   spectrometry	   to	  minimize	   the	  sample	  handling.	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   Modified	  from	  Astorga-­‐Wells	  et	  al78	  
Figure	  5.	  	  General	  principle	  of	  the	  microfluidic	  electrocapture	  technique.	  The	  electrocapture	  cell	  consists	  of	  two	  electrodes	  –	  the	  upstream	  electrode	  positively	  charged	  and	  the	  downstream	  electrode	  negatively	  charged.	  As	  charged	  molecules	  e.g.	  peptides	  are	  injected	  with	  a	  constant	  and	  continuous	  flow	  into	  the	  electrocapture	  cell,	  positively	  charged	  molecules	  tend	  to	  move	  towards	  the	  cathode	  (-­‐)	  and	  negatively	  charged	  molecules	  towards	  the	   anode	   (+).	  A.	   Immobilization	   is	   achieved	   through	   the	   counteracting	   effects	   of	   hydrodynamic	   and	   electric	  forces.	   When	   the	   hydrodynamic	   forces	   of	   the	   charged	   molecules	   are	   greater	   than	   the	   electric	   forces,	   the	  molecules	  are	  eluted.	  B.	  By	  gradually	  reducing	  the	  potential	  of	  the	  electrocapture	  cell,	  charged	  molecules	  can	  be	  separated	  in	  solution	  phase	  compatible	  for	  subsequent	  mass	  spectrometric	  analyses.	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Figure	  6.	  General	  principle	  of	  the	  microfluidic	  CD	  system.	  In	  the	  commercial	  discs	  previously	  available,	  there	  were	  96	  microstructures	  divided	  into	  6	  segments.	  Each	  segment	  had	  16	  microstructures	  with	  a	  common	  reagent	  inlet	  and	  a	  separate	  sample	  inlet.	  A	  sample	  of	  1-­‐5	  μl	  was	  loaded	  to	  the	  sample	  inlets.	  After	  spinning	  the	  CDs,	  the	  peptides	  were	  bound	  to	  the	  reverse	  phase	  column.	  The	  peptides	  were	  washed	  and	  eluted	  with	  a	  matrix	  to	  the	  target	   area.	   The	   CDs	  were	   then	   cut	   and	   applied	   to	   a	  MALDI	   target	   plate.	   External	   calibrant	   areas	   beside	   the	  MALDI	  target	  areas	  could	  be	  used	  during	  the	  MALDI-­‐MS	  analysis	  if	  internal	  calibration	  could	  not	  be	  used.	  	  
Bioinformatics	  in	  Proteomics	  The	   present	   high-­‐throughput	   screening	   technologies	   in	   genomics,	   transcriptomics	   and	  proteomics	   generate	   large	   amounts	  of	   data.	   Computational	   analysis,	   i.e.	   bioinformatics,	   is	   a	  key	  requirement	  for	  the	  study	  of	  large	  data	  sets.	  In	  this	  area	  of	  research,	  systems	  biology,	  a	  whole	   system	   rather	   than	   its	   components,	   is	   being	   studied82.	   The	   focus	   in	   proteomics	   has	  changed	   from	   small-­‐scale	   projects	   towards	   large-­‐scale	   studies	   and	   from	   qualitative	  expression	   patterns	   towards	   dynamics	   and	   turnover	   in	   different	   cell	   types	   and	   under	  different	  conditions.	  The	  emphasis	  is	  on	  the	  study	  of	  the	  global	  patterns	  in	  a	  cell,	  tissue	  or	  an	  organism,	  such	  as	  protein-­‐protein	  interactions	  and	  protein-­‐nucleotide	  interaction	  networks,	  metabolic	   pathways,	   signaling	   cascades	   networks,	   and	   gene	   and	   protein	   expression	  patterns83.	  To	  be	  able	  to	  extract	  the	  significant	  biological	  information	  from	  the	  large	  data	  sets,	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powerful	   computational	   tools	   are	   needed.	   Many	   of	   the	   bioinformatics	   strategies	   in	  proteomics	   can	   be	   adapted	   from	   the	   genomics,	   but	   there	   are	   also	   some	  unique	   features	   in	  proteomics,	   for	  example	   in	   the	   identification	  of	  proteins	  and	   in	   the	  study	  of	  PTMs.	  Systems	  biology	  can	  help	  us	  to	  understand	  the	  functions	  of	  cells,	  organs	  and	  organisms,	  as	  well	  as	  the	  pathogeneses	  of	  disease.	  	  
Protein	  identification	  The	  main	  goal	   of	  MS-­‐based	  proteomics	   is	   accurate	   identification	   and	   characterization	  of	   as	  many	   proteins	   as	   possible	   in	   the	   samples.	   	   A	   sample	   can	   be	   one	   protein	   or	   a	   mixture	   of	  proteins.	  Peptide	  mass	  fingerprinting	  (PMF)	  and	  peptide	  fragmentation	  fingerprinting	  (PFF)	  are	  the	  two	  main	  MS-­‐based	  approaches	  for	  the	  identification	  of	  proteins.	  	  A	  peptide	  mass	  fingerprint	  is	  obtained	  of	  a	  protein	  that	  has	  been	  enzymatically	  degraded	  with	  an	   amino	   acid-­‐specific	   protease	   such	   as	   trypsin.	   The	   sets	   of	   masses,	   typically	   obtained	   by	  MALDI-­‐TOF	   for	   isolated	  proteins,	   are	   then	  compared	   to	   the	   theoretically	  expected	   tryptical	  fragment	   masses	   for	   each	   entry	   in	   the	   databases	   (Swiss-­‐Prot84,	   NCBI85,	   TrEMBL86)	   using	  search	   engines	   such	   as	   ProteinProspector87	   and	   Mascot88.	   The	   proteins	   can	   be	   ranked	  according	  to	  the	  number	  of	  peptide	  matches.	  More	  sophisticated	  scoring	  algorithms	  take	  also	  into	   account	   the	  mass	   accuracy,	   the	   percentage	   of	   protein	   sequence	   covered,	   the	   rarity	   i.e.	  uniqueness	   of	   the	   peptide	   mass,	   the	   peptide	   mass	   specificity	   of	   a	   certain	   species,	   and	  calculate	  a	   level	  of	  confidence	  for	  the	  match89,90.	  The	  accuracy	  of	  the	  peptide	  masses	  affects	  also	  the	  specificity	  of	  the	  search.	  With	  MALDI-­‐TOF	  mass	  spectrometers,	  mass	  accuracy	  of	  <0.1	  Da	  can	  be	  achieved.	  	  Complex	  mixtures	  of	  peptides	  are	  analyzed	  by	  LC-­‐MS/MS-­‐based	  systems,	  which	  create	  first	  a	  PMF	  pattern	  of	  the	  peptides	  identified	  and	  then	  isolate	  them	  one	  by	  one	  and	  fragment	  them	  to	  create	  the	  sequence,	  an	  MS/MS	  spectrum.	  	  Theoretical	  MS/MS	  spectra	  are	  computed	  from	  the	   theoretical	   peptide	   sequences	   and	   correlated	  with	   the	   experimental	  MS/MS	   spectra	   to	  find	   the	   most	   similar.	   There	   are	   many	   available	   databases	   e.g.	   Mascot88,	   Phenyx91	   and	  SEQUEST92,	   that	   can	   analyze	   and	   validate	   	   the	   complex	   data	   obtained	   from	   the	   peptide	  mixtures.	  The	   search	   engines	   use	   different	   algorithms	   for	   the	   validation	   of	   protein	   identifications	   to	  overcome	  factors	  that	  might	  interfere	  with	  the	  identification	  process,	  such	  as	  the	  presence	  of	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contaminants,	  imprecise	  precursor	  masses,	  spectra	  derived	  from	  proteins	  not	  included	  in	  the	  database,	  unexpected	  PTMs	  and	  sequencing	  errors.	  Many	  search	  engines	  use	  statistical	  tools	  to	  calculate	  different	  scores,	  probabilities	  and	  false	  discovery	  rates	  for	  the	  identification.	  The	  algorithms	   are	   complex	   and	   take	   into	   account	   a	   number	   of	   parameters	   such	   as	   input	  parameters,	   number	   of	   peptides	   and	   amino	   acid	   sequences	   found/identified,	   the	   quality	   of	  the	  amino	  acid	   sequences,	  number	  of	  unique	  peptides	  and	  use	  of	   target-­‐decoy	  databases93.	  Target	   databases	   consist	   of	   true	   proteins	   with	   their	   peptides	   and	   sequencing.	   Decoy	  databases	   are	   constructed	   from	   reversed	   amino	   acid	   sequences,	   which	   do	   not	   occur	   in	  nature94.	  	  	  	  
Normalization	  of	  data	  The	  initial	  steps	  in	  the	  interpretation	  of	  the	  long	  lists	  of	  identified	  proteins	  is	  to	  normalize	  the	  protein	  names	   to	   specific	   identifiers	  because	  different	  databases	  may	  have	  different	  names	  and	  the	  names	  may	  change	   in	   the	  updated	  versions.	  Uniprot95,	  Ensembl96	  and	   international	  protein	  index	  (IPI)97	  identifiers	  are	  most	  commonly	  used.	  	  There	  are	  several	  tools98,99	  to	  do	  it,	  so	  one	  does	  not	  have	  to	  do	  it	  manually.	  	  There	  are	  also	  tools,	  which	  can	  be	  used	  to	  compare	  proteomic	  results	  to	  related	  experiments	  performed	  by	  other	  groups	  in	  the	  past100,101.	  	  
Gene	  Ontology	  To	   describe	   a	   gene	   or	   protein	   and	   its	   functions	   by	   a	   definite	   vocabulary,	   Gene	   Ontology	  (GO)102	  was	  created.	  In	  this	  way,	  laboratories	  all	  around	  the	  world	  can	  categorize	  their	  results	  in	   a	   similar	   manner.	   In	   GO,	   genes	   and	   proteins	   are	   categorized	   in	   three	   GO-­‐categories:	  biological	  process,	  molecular	  function	  and	  cellular	  component.	  The	  Database	  for	  Annotation,	  Visualization	   and	   Integrated	   Discovery	   (DAVID)103	   is	   a	   popular	   and	   free	   internet-­‐based	  program	  used	   for	  GO-­‐annotation	  of	   large	  datasets.	   	  However,	   it	   is	   important	   to	  be	  aware	  of	  that	  all	  genes	  and	  proteins	  are	  not	  annotated	  in	  GO-­‐terms.	  	  
Pathway	  analysis	  and	  interaction	  networks	  A	  biological	  pathway	   consists	   of	   a	   series	  of	  well-­‐defined	  protein	   interactions	   that	   lead	   to	   a	  specific	  biological	  outcome.	  With	  pathway	  analysis	  it	  is	  possible	  to	  identify	  the	  most	  relevant	  signaling	  and	  metabolic	  pathways	  of	  the	  experimental	  data.	  Pathways	  are	  manually	  curated	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from	   the	   published	   data.	   There	   are	   still	   unknown	   or	   poorly	   studied	   proteins,	   that	   are	   not	  included	   in	  any	  pathways.	  This	  must	  be	   taken	   into	  account	  during	   the	  analysis	  of	   the	  data.	  Kyoto	  Encyclopedia	  of	  Genes	  and	  Genomes	  (KEGG)104	  and	  Ingenuity	  Pathway	  Analysis	  (IPA)	  (www.ingenuity.com)	  provide	  good	  models	  for	  hundreds	  of	  pathways.	  	  Interaction	   networks	   are	   based	   on	   known	   relationships	   of	   proteins	   in	   databases.	   Protein-­‐protein	   interactions	   (PPIs)	   comprise	   both	   physical	   and	   functional	   interactions.	   Physical	  interactions	   include	  for	  example	  the	   formation	  of	  multiprotein	  complexes,	  such	  as	  the	  actin	  cytoskeleton	   network.	   Functional	   interactions	   include	   for	   example	   sharing	   of	   a	   common	  substrate	   in	  a	  pathway	  or	   inhibition,	  or	  activation	  of	  each	  other	  at	   the	  transcriptional	   level.	  The	  Human	  Protein	  Reference	  Database	  (HPRD)105	  contains	  approximately	  40,000	  manually	  curated	  human	  PPIs.	  	  There	  are	  several	  tools	  that	  can	  be	  used	  to	  visualize	  interactions	  and	  networks.	  As	  mentioned	  above,	  KEGG	   and	   IPA	  databases	   are	   used	   for	   the	   study	   of	   pathways.	   IPA	   software	   can	   also	  construct	  networks.	  Another	  software	  to	  construct	  software	  is	  Cytoscape106.	  With	  the	  help	  of	  these	   bioinformatics	   tools	   it	   is	   possible	   to	   validate	   large	   data	   sets,	   i.e.	   expressed	  genes/proteins	  in	  normal	  cells	  or	  disease	  models	  by	  concretely	  seeing	  which	  components	  and	  pathways	   are	   most	   relevant	   for	   the	   experimental	   data.	   The	   results	   may	   also	   imply	   novel	  connections	   to	   pathways	   and	   processes	   and	   may	   be	   helpful	   in	   the	   discovery	   of	   novel	  biomarkers.	   It	   is	   important	   to	   appreciate	   that	   the	   tools	   do	   not	   give	   definite	   answers,	   but	  instead	   help	   scientists	   to	   develop	   testable	   hypotheses,	   which	   need	   to	   be	   evaluated	   in	   the	  laboratory.	  	  	  
Kidney	  filtration	  system	  
Kidney	  glomerulus	  The	  kidney	  glomerulus	   is	   the	   filtration	  unit	  of	   the	  kidney	   (Figure	  7).	   It	   consists	  of	   a	   tuft	  of	  capillaries	   surrounded	   by	   a	   Bowman’s	   capsule	   at	   the	   proximal	   end	   of	   the	   nephron.	   It	  functions	   as	   a	   high-­‐capacity	   molecular	   sieve	   through	   which	   plasma	   is	   filtered	   into	   the	  Bowman’s	   space	   as	   primary	   urine.	   The	   glomerular	   filtration	   barrier	   is	   composed	   of	  glomerular	   fenestrated	   endothelial	   cells,	   a	   basement	   membrane	   (GBM)	   and	   an	   epithelial	  podocyte	   cell	   monolayer107,108.	   The	   cell	   body	   of	   a	   podocyte	   lies	   in	   the	   urinary	   space	   and	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extends	   primary,	   secondary	   and	   finally	   fine	   terminal	   foot	   processes	   that	   cover	   the	   outer	  surface	   of	   the	   basement	   membrane	   in	   an	   interdigitating	   manner.	   Between	   the	   fine	   foot	  processes	  remains	  a	  narrow	  40	  nm	  wide	  slit.	  Adjacent	  foot	  processes	  are	  interconnected	  with	  a	  cell-­‐cell	  junction	  referred	  to	  as	  slit	  diaphragm,	  that	  comprises	  the	  ultimate	  filter109,110.	  	  	  	  
	  	   	   	   	   	   	   Modified	  from	  Tryggvason	  and	  Wartiovaara111	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Table	   1.	   Classification	   of	   acquired	   kidney	   diseases.	   This	   table	   illustrates	   a	   simplified	   classification	   of	  glomerular	   diseases	   based	   on	   pathology,	   together	   with	   the	   manifesting	   syndrome,	   etiology,	   morphological	  changes	  and	  deposits	  characteristic	  for	  the	  respective	  diseases.	  
	   	   	   	   	   	  
Table	  2.	  Inherited	  glomerular	  diseases	  and	  their	  clinical	  manifestations.	  
	  	  
Disease Syndrome Etiology Morphological changes Deposits




Mesangial proliferative GN Nephritic syndrome Mesangial expansion
immune-complexes in the 
mesangium
Membranoproliferative GN Nephrotic/nephritic 
syndrome
GBM thickening, double contour 
capillary wall, mesangial expansion
immune-complexes and 
complement  in the 
subendothelial space and GBM
Focal proliferative GN (IgA) Nephritic syndrome unknown GBM thickening IgA in the mesangium








subendothelial and subepithelial 
locations




cellular proliferation of parietal epithelial 
cells and Inflammatory cell infiltrates in 
the Bowman's capsule
ANCA or IgG in GBM
Non-proliferative glomerulonephritis
Minimal change disease Nephrotic syndrome Effacement of podocyte foot processes -
Focal segmental glomerulosclerosis Nephrotic syndrome
Focal segmental sclerosis, mesangial 
expansion -
Membranous nephropathy Nephrotic syndrome GBM thickening Immune complexes in 
subepithelial layer
Hereditary nephritis
Alport's syndrome Nephritic syndrome Mutations in COL4A3, 
COL4A4 or COL4A5
Thickening, thinning and splitting of GBM -
Chronic glomerulonephritis
Extensive tubular atrophy, interstitial 





hepatitis B or C, HIV






Type IV collagen Mainly autosomal recessive, 
X-linked (COL4A5)
Nephritic syndrome at adolescence or 
early adulthood. Thickening, thinning 
and splitting of GBM
Pierson's Disease LAMB2 Laminin !2 Autosomal recessive
Lethal nephrotic syndrome at birth, 
diffuse mesangial sclerosis
Congenital nephrotic syndrome of the 
Finnish type (CNF)
NPHS1 Nephrin Autosomal recessive
Nephrotic syndrome after birth, foot 
process effacement and absence of slit 
diaphragm.
Steroid-resistant nephrotic syndrome NPHS2 Podocin Autosomal recessive
Usually onset at early childhood, steroid 
resistant, rapid progression, Nephrotic 
syndrome, FSGS
Focal segmental glomerulosclerosis ACTN4 "-actinin 4 Autosomal dominant
Nephrotic syndrome at adolescence, 
slow progression
Focal segmental glomerulosclerosis TRPC6 Transient receptor 
potential cation channel 6
Autosomal dominant Nephrotic syndrome at adulthood
Focal segmental glomerulosclerosis CD2AP CD2-associated protein Autosomal recessive Nephropathy at infancy, rapid progresion
Familial diffuse mesangial sclerosis PLCE1 Phospholipase C, epsilon 1Autosomal recessive Nephrotic syndrome at early childhood
Galloway-Mowat syndrome ?? Nephrotic syndrome at infancy of age, FSGS
Denys-Drash syndrome WT1 Wilms tumor oncogene 1 Autosomal recessive Nephropathy at infancy, rapid 
progression, diffuse mesagial sclerosis
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Glomerulonephritis	   encompasses	   a	   wide	   range	   of	   immune-­‐mediated	   disorders	   that	   cause	  inflammation	  in	  the	  glomerulus.	  The	  pathomechanisms	  of	  glomerulonephritides	  are	  complex	  and	   not	   understood.	   First,	   many	   types	   of	   insults	   can	   initiate	   glomerulonephritis	   e.g.	  endogenous	   processes	   such	   as	   autoimmune	   disorders,	   cancers,	   structural	   abnormalities	   of	  glomeruli,	   and	   exogenous	   factors	   such	   as	   infectious	  organisms,	   toxins	   and	  drugs.	   Secondly,	  there	  are	  also	  individual	  differences	  in	  the	  susceptibility	  to	  glomerulonephritis.	  Thirdly,	  there	  are	  complex	  interactions	  between	  different	  inflammatory	  mediators	  (antibodies,	  chemokines,	  complement,	  growth	  factors)	  and	  cells	  (macrophages,	  T-­‐cells)	  occurring	  at	  the	  same	  time.	  A	  final	   cause	   of	   complexity	   is	   the	   progressive	   nature	   of	   many	   of	   the	   kidney	   diseases,	   with	  factors	  such	  as	  hypertension	  and	  proteinuria	  promoting	  the	  continuing	  glomerular	  damage.	  	  Podocyte	   injury	   and	   effacement	   of	   the	   foot	   processes	   results	   in	   excessive	   proteinuria,	   and	  therefore	  podocytes	  are	   frequently	   the	  primary	   targets	  of	   interest	   in	  studies	  on	  glomerular	  diseases.	   Alport	   syndrome,	   a	   genetic	   disorder	   of	   type	   IV	   collagen	   in	   the	   basal	   lamina,	   only	  results	   in	   modest	   proteinuria.	   It	   is	   believed	   that	   the	   development	   of	   proteinuria	   with	  systematic	   diseases	   is	   probably	   a	   multistep	   process.	   The	   endothelium	   is	   first	   damaged	   to	  produce	  more	  components	  of	  the	  GBM	  as	  the	  negatively	  charged	  glycocalyx	  also	  disrupts	  and	  loses	  its	  ability	  to	  repulse	  the	  negatively	  charged	  proteins.	  The	  organization	  of	  actin	  skeleton	  of	   the	  podocytes	   is	   then	  slowly	  disrupted	  and	  podocyte	   injury	  and	   foot	  process	  effacement	  occurs,	   which	   results	   in	   proteinuria.	   Even	   though	   the	   structure	   of	   the	   glomerular	   filter	   is	  quite	   well	   known,	   the	   molecular	   understanding	   of	   the	   pathomechanisms	   that	   lead	   to	  proteinuria	  are	  still	  poorly	  understood	  and	  therefore	  we	  are	  still	  lacking	  specific	  therapies	  for	  kidney	  diseases.	  	  In	   the	   clinic,	   diagnosis	   of	   the	   glomerular	   disease	   is	   important	   because	   the	   outcome	   and	  treatment	   differs	   with	   different	   types.	   Many	   cases	   of	   glomerulonephritis	   result	   in	   mild	  asymptomatic	   illness	   that	   is	   not	   recognized	   by	   the	   patients.	   They	  might	   have	  microscopic	  hematuria	  or	  subnephrotic	  range	  proteinuria	  with	  normal	  renal	   function.	  Signs	  of	  nephritic	  syndrome	   include	   recent	   onset	   of	   hematuria,	   proteinuria,	   renal	   impairment,	   and	   salt	   and	  water	   retention	   causing	   hypertension.	   The	   characteristics	   for	   nephrotic	   syndrome	   are	  proteinuria	   (>3.5g/1.73m2/24h),	   hypoalbuminemia,	   edema	   and	   hyperlipidemia.	   Chronic	  glomerulonephritis	   includes	   persistent	   proteinuria	   with	   or	   without	   hematuria	   and	   slowly	  progressive	  impairment	  of	  renal	  function.	  Kidney	  disease	  diagnostics	  involve	  laboratory	  tests	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and	   biopsy.	   Typical	   laboratory	   diagnostics	   of	   renal	   diseases	   include:	   blood	   pressure,	   S/P-­‐creatinine,	  S/P-­‐albumin,	  urine	  analysis,	  dU-­‐albumin,	  cystatin-­‐C	  and	  S/P-­‐urea.	  Renal	   function	   and	   the	   stage	   of	   chronic	   kidney	   disease	   are	   determined	   by	   the	   glomerular	  filtration	   rate	   (GFR).	   It	   describes	   the	   flow	   rate	   of	   filtered	   fluid	   through	   the	   kidney.	   The	  Cockcroft-­‐Gault	   equation	   is	   the	   most	   commonly	   used	   formula	   used	   to	   calculated	   the	   GFR	  when	   serum/plasma	   creatinine	   is	   known.	   GFR	   for	   a	   healthy	   person	   is	   100-­‐140	   ml/min.	  Chronic	  kidney	  disease	  patients	  with	  GFR	  <	  15	  ml/min	  are	  subjected	  to	  kidney	  replacement	  therapy.	  	  Glomerular	  expression	  profiling,	  both	  with	  regard	  to	  protein	  and	  RNA	  expression	  are	  limited.	  No	  glomerular	  proteome	  analyses	  existed	  at	   the	  beginning	  of	   the	  present	  project,	   and	  only	  limited	  amount	  of	  information	  had	  been	  reported	  on	  glomerular	  transcriptomes	  (Paper	  V).	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AIMS	  OF	  THE	  THESIS	  The	  aims	  of	  my	   thesis	  have	  evolved	  during	  my	   time	  as	   a	  PhD	   student.	  The	   initial	   goal	  was	  limited	   to	   characterize	   the	   glomerular	   proteomes	   in	   healthy	   and	   diseased	  mice	   to	   provide	  new	   knowledge	   about	   the	   protein	   composition	   of	   glomeruli	   and	   pathomechanisms	   in	  glomerular	  diseases.	  	  As	  my	  studies	  were	  elongated	   in	   time	  by	  my	  parallel	  work	  with	  my	  medical	  education,	   the	  aims	  were	  extended	  to	  get	  a	  more	  general	  view	  of	  proteomics	  and	  to	  include	  an	  insight	  into	  new	  technical	  methodologies	  in	  the	  field,	  still	  having	  the	  emphasis	  on	  the	  kidney	  glomerulus.	  Paper	  II	  was	  a	  straightforward	  proteomic	  study	  of	  the	  glomerular	  proteome.	  Papers	  I,	  III	  and	  IV	   involved	   the	   participation	   in	   the	   development	   of	   new	   technologies	   in	   proteomics	   and	  finally	  I	  addressed	  my	  interest	  on	  the	  importance	  of	  proteome	  and	  transcriptome	  studies	  of	  glomerular	  disease	  from	  the	  clinical	  point	  of	  view	  (Paper	  V).	  	  Specific	  aims	  of	  the	  study	  have	  been:	  
• Characterization	  of	   endothelial	   proteins	   in	  human	   saphenous	   vein	   endothelial	   cells	   using	   a	  novel	   high	   throughput	   CD-­‐based	   technology	   for	   sample	   preparation	   prior	   to	   MALDI-­‐MS	  (Paper	  I)	  	  
• Characterization	   of	   mouse	   glomerular	   proteins	   by	   2-­‐D	   gel	   electrophoresis	   and	   mass	  spectrometry	  (Paper	  II)	  	  
• Development	   of	   a	   novel	   microfluidic	   electrocapture	   technology	   for	   separation	   of	   peptides	  (Paper	  III)	  	  
• Characterization	   of	   glomerular	   membrane	   proteins	   using	   electrocapture	   and	   mass	  spectrometry,	  a	  novel	  two-­‐dimensional	  system	  for	  proteomic	  analysis	  (Paper	  IV)	  	  
• Meta-­‐analysis	  of	  current	  data	  on	  pathways	  and	  networks	  in	  glomerular	  disease	  (Paper	  V)	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MATERIALS	  AND	  METHODS	  This	  chapter	  includes	  a	  brief	  overview	  of	  the	  methods	  used	  in	  this	  thesis.	  Detailed	  description	  of	  the	  materials	  and	  methods	  can	  be	  found	  in	  the	  corresponding	  papers.	  	  
Sample	  Preparation	  
Isolation	  of	  glomeruli	  (Paper	  II,	  IV)	  Kidney	  glomeruli	  were	  isolated	  from	  mice	  according	  to	  Takemoto	  et	  al137.	  Briefly,	  mice	  were	  anesthetized	  by	  an	  intraperitoneal	  injection	  of	  20	  μL/g	  of	  2%	  (w:v)	  Avertin	  [100%	  stock	  (5	  g	  2,2,2-­‐tribromoethyl	   in	   5	   ml	   tertiary	   amyl	   alcohol)	   diluted	   in	   sterile	   H2O].	   The	   mice	   were	  perfused	   with	   HBSS	   containing	   8	   x	   107	   magnetic	   Dynabeads®	   (Dynal)	   through	   the	   left	  ventricle	  via	  vena	  cava	  superior.	   	  The	  kidneys	  were	  removed,	  minced	   into	  small	  pieces	  and	  digested	  with	  DNase	  I	  for	  30	  min	  at	  37	  °C.	  The	  digested	  tissue	  was	  pressed	  though	  a	  100	  μm	  cell	   strainer	   and	   washed	   two	   times.	   Finally	   the	   glomeruli	   were	   collected	   with	   a	   magnetic	  particle	  collector	  (Dynal)	  and	  washed.	  The glomeruli were counted and the purity was controlled 
under a light microscope.	  	  
Sample	  preparation	  for	  2-­‐DE	  	  (Paper	  I,	  II)	  
Human	  vena	  saphena	  endothelial	  cells	  (Paper	  I)	  Human	  endothelial	  cells	  from	  vena	  saphena	  magna	  (Paper	  I)	  were	  isolated	  during	  coronary	  bypass	   operations	   and	   then	   grown	   under	   laboratory	   conditions.	   Protein	   samples	   were	  prepared	  according	  to	  the	  BioRad	  ReadyPrep	  Kit.	  Isolated	  human	  vein	  endothelial	  cells	  were	  suspended	  in	  50	  mM	  Tris-­‐buffer	  and	  disrupted	  with	  6x10s	  sonication	  bursts.	  The	  sample	  was	  centrifuged	   for	   15	   min	   at	   13,000g	   and	   the	   supernatant	   was	   collected.	   The	   pellet	   was	  dissolved	   in	   8	   M	   urea,	   4%	   CHAPS,	   40	   mM	   Tris,	   0.2%	   w/v	   Biolyte	   3/10	   and	   2	   mM	  tributylphosphine.	  Protein	  concentrations	  were	  measured	  using	  the	  Bradford	  assay138.	   	  The	  protein	  sample	  of	  the	  supernatant	  was	  used	  for	  the	  2-­‐DE	  analysis.	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Mouse	  glomeruli	  (Paper	  II)	  Isolated	   glomeruli	   (Paper	   II)	  were	   suspended	   in	  water,	   freeze-­‐thawed	   four	   times	   in	   liquid	  nitrogen	   and	   freeze-­‐dried	   under	   vacuum.	   Dried	   samples	   were	   solubilized	   in	   a	   lysis	   buffer	  containing	   9M	   urea,	   65	  mM	  DTT,	   2%	   CHAPS,	   0.5%	  NP-­‐40,	   35	  mM	  Tris,	   protease	   inhibitor	  cocktail	  tablet	  (Roche)	  in	  a	  shaker	  for	  4	  h.	  In	  this	  manner,	  almost	  all	  proteins	  were	  dissolved	  in	  the	  same	  sample.	  	  
Sample	  Preparation	  for	  EC-­‐based	  studies	  
Protein	  stock	  solution	  (Paper	  III)	  Protein	  stock	  solutions	  (Paper	  III)	  of	  standard	  proteins	  were	  prepared	  at	  concentration	  of	  1-­‐5	  mg/ml	   of	   10	   proteins.	   	   Carbamidomethylation	   of	   cysteine	   residues	   was	   carried	   out	   by	  incubation	   of	   25	   μl	   of	   protein	   solution	   with	   5	   μl	   of	   45	   mM	   DTT	   at	   50	   °C	   for	   15	   min	   and	  subsequent	   incubation	   with	   5	   μl	   of	   100	   mM	   IAA	   at	   room	   temperature	   for	   15	   min.	   After	  alkylation,	  reagents	  were	  diluted	  by	  addition	  of	  Tris-­‐HCl	  (64	  μl	  of	  40	  mM,	  pH	  8),	  and	  digested	  overnight	   at	   37	   °C	   by	   addition	   of	   1	   μl	   of	   trypsin	   (1	   μg/μl	   in	   50	  mM	   acetic	   acid).	   Resulting	  digests	  were	  stored	  at	  –20	  °C.	  	  
Membrane	  proteins	  from	  mouse	  kidney	  (Paper	  III)	  Tissue	  from	  mouse	  kidney	  was	  washed	  in	  500	  μl	  of	  12.5	  mM	  NH4HCO3	  and	  incubated	  on	  ice	  for	   30	   min.	   The	   sample	   was	   then	   treated	   by	   five	   freeze/thaw	   cycles	   in	   liquid	   nitrogen,	  sonicated	  4	   times	   for	  10s	  and	  centrifuged	   for	  5	  min	  at	  2,000	  g,	  after	  which	  the	  supernatant	  was	  discarded.	  The	  pellet	  was	  resuspended	  in	  500	  μl	  of	  12.5	  mM	  NH4HCO3	  and	  centrifuged	  at	  6,000	   g	   for	   10	   min.	   The	   supernatant	   was	   transferred	   to	   an	   ultracentrifuge	   tube	   and	  centrifuged	  at	  80,000	  g	  for	  30	  min	  (Beckman	  Ti	  70.1).	  The	  supernatant	  was	  discarded	  and	  the	  pellet	  dissolved	  in	  25	  mM	  NH4HCO3.	  The	  resulting	  sample	  was	  ultracentrifuged	  at	  100,000	  g	  for	  1	  h.	  The	  supernatant	  was	  discarded	  and	  the	  pellet	  suspended	  in	  1.5	  ml	  of	  100	  mM	  Na2CO3,	  pH	  11.3	  and	  centrifuged	  at	  13,000	  rpm	  at	  4	  °C.	  The	  pellet	  was	  solubilized	  in	  50	  mM	  NH4HCO3,	  pH	  7.9,	  1%	  CHAPS.	  For	  digestion,	  1	  μl	  of	  trypsin	  (1	  μg/μl	  in	  50	  mM	  acetic	  acid)	  was	  added	  to	  100	  μl	  of	  sample.	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Membrane	  proteins	  from	  mouse	  glomeruli	  (Paper	  IV)	  Isolated	  glomeruli	  were	  dissolved	  in	  30	  mM	  HEPES	  (pH	  7.8)	  with	  protease	  inhibitors	  (Roche).	  Glomeruli	  were	  disrupted	  by	  6	  cycles	  of	   freeze/thawing	   in	   liquid	  nitrogen.	  The	  sample	  was	  centrifuged	  at	  13,000g.	  The	  pellet	  was	  dissolved	  in	  65	  mM	  HEPES,	  2%	  CHAPS	  and	  protease	  inhibitor	  tablet	  (Roche).	  The	  proteins	  were	  reduced	  in	  10	  mM	  DTT	  ad	  56	  °C,	  alkylated	  in	  35	  mM	  IAA	  and	  digested	  with	  trypsin	  (0.03	  μg/μl)	  overnight.	  	  	  
Two-­‐dimensional	  gel	  electrophoresis	  (Paper	  I,	  II)	  In	  paper	  I,	  IEF	  was	  carried	  out	  on	  13	  cm	  IPG	  strips	  (Amersham	  Biosciences).	  The	  strips	  were	  rehydrated	  overnight.	  A	  sample	  of	  10	  μg	  was	  loaded	  for	  Sypro	  Ruby®	  staining	  and	  100	  μg	  for	  CBB	   staining.	   It	   was	   carried	   out	   with	   Multiphor	   II	   (Amersham	   Biosciences)	   for	   a	   total	   of	  57,400	  Vh.	  The	  SDS-­‐PAGE	  was	  performed	  on	  10	  %	  gels	  and	  stained.	  	  In	  paper	  II,	  IEF	  was	  performed	  on	  17	  cm	  IPG	  strips	  (BioRad)	  with	  pI	  4-­‐7	  and	  3-­‐10.	  The	  strips	  were	  actively	  rehydrated	  for	  12	  h.	  75	  μg	  was	  loaded	  for	  silver	  stained	  gels	  and	  500	  μg	  for	  CBB	  stained	  gels.	  The	  focusing	  was	  carried	  out	  in	  an	  IEF	  cell	  (BioRad)	  with	  a	  total	  of	  35,000	  Vh	  for	  pI	  4-­‐7	   strips	   and	  51,000	  Vh	   for	  pI	  3-­‐10	   strips.	  The	   second	  dimension	  was	  performed	  on	  8-­‐16%	  gradient	  SDS-­‐PAGE	  gels	  with	  Ettan™	  DALTSix.	  
	  
In-­‐gel	  digestion	  (Paper	  I,	  II)	  In-­‐gel	  digestion	  was	  performed	  in	  an	  automated	  MassPrep	  station	  (Micromass/Waters).	  Gel 
pieces were destained twice in 100 μL 50 mM Ambic / 50% (v/v) acetonitrile at 40°C for 10 min. 
Proteins were reduced with 10mM DTT in 100 mM Ambic for 30 min and alkylated with 55 mM 
iodoacetamide (IAA) in 100 mM Ambic for 20 min. Proteins were digested with trypsin (12 ng/μL 
solution in 50 mM Ambic) for 4.5 h at 40°C. The peptides were extracted with 30 μL 5% formic 
acid / 2% acetonitrile followed by 24 μL 2.5% formic acid / 50% acetonitrile.  	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Desalting	  and	  concentration	  of	  peptide	  samples	  prior	  to	  MS	  
(Paper	  I,	  II)	  Peptide	  samples	  were	  desalted	  and	  concentrated	  either	  manually	  using	  ZipTips	  (Millipore)	  or	  with	  the	  CD-­‐based	  microfluidic	  technology	  (Gyros	  AB)	  according	  to	  similar	  procedures.	  The	  C18-­‐RPC	   column	   was	   activated	   with	   50%	   AcN/0.1%	   TFA	   solution,	   ZipTips	   were	   then	  equilibrated	  with	  0.1%	  TFA	   (the	  CD-­‐based	   system	  skipped	   this	   step).	  10	  µL	  of	   sample	  was	  loaded	  with	   the	  ZipTips	  and	  1	  µL	  with	   the	  CD-­‐system.	  Peptides	  were	  wash	  with	  0.1%	  TFA.	  Finally	  peptides	  were	  eluted	  with	  5-­‐10	  µL	  75%	  AcN/0.1%	  TFA.	  Aliquots	  of	  1	  µL	  sample	  was	  mixed	   with	   1:1	   (v/v)	   of	   saturated	   α-­‐cyano-­‐hydroxy-­‐cinnamic	   acid	   matrix	   in	   in	   60%	  AcN/0.1%	  TFA.	  	  In	  the	  CD-­‐based	  method	  the	  peptides	  were	  eluted	  with	  50%	  AcN/0.1%	  TFA	  mixed	  with	  the	  matrix.	  	  
Mass	  Spectrometry	  
MALDI-­‐TOF	  Voyager	  DE-­‐Pro	  (paper	  I,	  II,	  III)	  
MALDI-TOF Voyager DE-Pro (Applied Biosystems) and MALDI-Q-TOF Ultima (Waters) was 
used for PMF.	   The	  mass	   spectra	  were	   obtained	   using	   a	   Voyager	   DE-­‐PRO	  MALDI-­‐TOF	  mass	  spectrometer	   (Applied	   Biosystems)	   operated	   in	   the	   positive	   ion	  mode.	   The	   reflector	  mode	  was	  used	  at	  20	  kV	  accelerating	  voltage,	  74.5	  %	  grid	  voltage,	  0.005	  %	  guide	  wire	  and	  200	  ns	  delayed	   extraction.	   Calibration	   was	   performed	   internally	   with	   the	   tryptic	   peptides	   of	   the	  samples	  (Paper	  I,	  II).	  In	  paper	  III	  the	  calibration	  was	  performed	  with	  Sequazyme	  Peptide	  Mass	  Standard	   (Applied	   Biosystems)	   with	   the	   α-­‐cyano	   matrix.	   	   Identification	   of	   proteins	   was	  performed	  using	  the	  ProteinProspector	  MS-­‐Fit	  and	  Mascot	  search	  engines.	  	  
MALDI-­‐Q-­‐TOF	  Ultima	  (paper	  II)	  The	  MALDI-­‐Q-­‐TOF	  Ultima	  	  (Micromass)	  instrument	  was	  calibrated	  with	  a	  polyethylene	  glycol	  standard	   between	   80–2500	   m/z,	   and	   was	   operated	   in	   single	   reflector	   mode	   and	   in	   the	  positive	  ion	  mode.	  The	  MS	  software,	  MassLynx	  Version	  3.4,	  was	  used	  to	  create	  a	  peak	  list,	  and	  a	  macro	  MaxEnt3	  (800-­‐3000	  Da,	  single	  charged	  ions,	  peak	  width	  0.1	  Da)	  was	  applied	  for	  each	  list	  before	  submission	  into	  the	  Mascot	  search	  engine.	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LC-­‐API	  Q-­‐TOF	  Ultima	  (Paper	  II,	  IV)	  An	  LC-­‐API	  Q-­‐TOF	  Ultima	  tandem	  mass	  spectrometer	  (Waters)	  was	  utilized	  for	  the	  analysis	  of	  amino	   acid	   sequences	   of	   samples	   that	   could	   not	   be	   identified	  with	  MALDI-­‐MS.	   Prior	   to	   LC-­‐	  separation,	  digests	  were	  desalted	  with	  an	  Atlantis	  dC18	  5-­‐μm	  NanoEase	  Trap	  column	  using	  20	  μL	   of	   0.1%	   formic	   acid.	   	   Peptides	   were	   then	   separated	  with	   an	   analytical	   column	   (Waters	  Atlantis	   C18,	   3	   μm,	   100	   Å,	   75	   μm	   i.d	   x	   15	   cm)	   and	   the	   peptides	   were	   eluted	   with	   a	   linear	  gradient	  of	  5-­‐80%	  acetonitrile	  in	  0.1%	  formic	  acid	  (Solvent	  A:	  5%	  AcN/0.1%	  TFA,	  Solvent	  B	  95%	   AcN/0.1%	   TFA)	   for	   42	  min	   at	   200	   nL/min	   (Paper	   II)	   and	   for	   45	  min	   at	   200	   nL/min	  (Paper	   IV).	   Peptides	   were	   introduced	   into	   the	   mass	   spectrometer	   using	   a	   PicoTip	   Emitter	  (SilicaTip,	  New	  Objective)	  and	  data-­‐dependent	  acquisition	  (DDA)	  was	  employed	  over	  a	  mass	  range	   of	   300-­‐1600	   m/z	   (Paper	   II)	   and	   300-­‐2,000	   m/z	   (Paper	   IV).	   Data	   analysis	   was	  performed	   using	   ProteinLynx	   Global	   SERVER	   2.2.3	   software	   (PLGS	   2.2.3,	   Waters)	   and	  MassLynx	   4.1	   peptide	   sequence	   software.	  Mascot	   (Paper	   II)	   and	   Phenyx	   (Paper	   IV)	   search	  engines	  were	  used	  for	  protein	  identification.	  	  
Microfluidic	  electrocapture	  (Paper	  III,	  IV)	  The	  microfluidic	  electrocapture	  was	  manufactured	  using	  a	  piece	  of	  poly(ether-­‐ether-­‐ketone)	  (PEEK)	   tubing	   (512	   μm	   o.d.,	   127	   μm	   i.d,	   Upchurch	   Scientific).	   Two	   small	   openings	   2.6	   cm	  apart	   were	   made	   and	   covered	   with	   a	   conductive	   tubular	   cation-­‐selective	  poly(tetrafluoroethylenesulfonate)	  membrane	   (Permapure	   inc)	  with	  dimesions	   (330	  μm	   i.d.	  and	  610	  μm	  o.d.).	  The	  junctions	  were	  placed	  into	  separate	  electrode	  chambers	  made	  from	  500	  μL	   Eppendorf	   tubes	   (Eppendorf)	   and	   filled	   with	   40	   mM	   Tris-­‐HCl	   (pH	   8).	   Electrodes	   of	  platinum	  wire	  were	  placed	  into	  the	  tubes.	  The	  anode	  was	  connected	  to	  a	  high	  voltage	  power	  supply	  and	  the	  cathode	  was	  grounded.	  A	  syringe	  pump	  (Harard	  Apparatus)	  equipped	  with	  a	  100	  μL	  gas-­‐tight	  syringe	  (Hamilton),	   that	  was	   filled	  with	  40	  mM	  Tris-­‐HCl	  (pH	  8)	  provided	  a	  continuous	   hydrodynamic	   flow	   of	   0.2	   μL/min.	   The	   syringe	   pump	   was	   connected	   with	   a	  microinjector	  with	  a	  1	  μL	  (Paper	  III)	  or	  4	  μL	  (Paper	  IV)	   internal	   loop.	  Using	  this	  system	  the	  sample	  manipulation	  was	  minimized.	  	  In	  paper	  III,	  the	  anode	  was	  situated	  on	  the	  downstream	  and	  the	  cathode	  on	  the	  upstream	  gap	  of	  the	  cell.	  The	  initial	  voltage	  of	  the	  electrocapture	  was	  139	  V/cm,	  and	  the	  flow	  rate	  was	  0.2	  μL/min.	  After	  sample	  injection,	  the	  peptides	  were	  captured	  for	  45	  min	  (Paper	  III).	  The	  voltage	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was	   the	   reduced	   with	   5-­‐10V	   every	   minute,	   the	   samples	   were	   collected	   and	   analyzed	   with	  MALDI-­‐TOF	   Voyager	   DE-­‐Pro.	   For	   a	   single	   protein	   of	   200	   fmol	   phosphorylase	   b,	   the	   initial	  voltage	  was	  98	  V/cm	  and	  was	  reduced	  9-­‐15	  volts	  in	  every	  step.	  	  In	  paper	  IV,	  the	  anode	  was	  situated	  on	  the	  upstream	  and	  the	  cathode	  on	  the	  downstream	  gap	  of	  the	  cell.	  By	  this	  way,	  the	  EC	  captured	  best	  negatively	  charged	  molecules.	  The	  initial	  voltage	  was	  set	  to	  200	  V,	  the	  continuous	  flow	  rate	  at	  0.2	  μL/min.	  Peptides	  were	  captured	  for	  40	  min	  and	  then	  the	  potential	  was	  reduced	  by	  10	  V	  every	  30	  min.	  Eluted	  fractions	  were	  collected	  for	  15	  min,	  followed	  by	  a	  15	  min	  washing	  period.	  3	  μL	  of	  0.3%	  formic	  acid	  was	  added	  before	  the	  analysis	  of	  the	  samples	  with	  the	  LC-­‐MS/MS	  system.	  	  
Meta-­‐analysis	  of	  glomerular	  proteomes	  and	  transcriptome	  
studies	  (Paper	  V)	  The	  aim	  was	  to	  compile	  all	  reported	  proteomic	  and	  transcriptomic	  data	  for	  healthy	  glomeruli,	  and	   glomeruli	   isolated	   from	   animal	  models	   and	   human	   patients	   with	   different	   glomerular	  diseases,	  in	  order	  to	  get	  insight	  into	  expression	  signatures.	  It	  can	  be	  anticipated	  that	  different	  types	   of	   glomerular	   disease	   processes	   exhibit	   disease	   specific	   expression	   patterns,	   so	   one	  may	   be	   able	   to	   get	   new	   understanding	   of	   the	   pathomechanisms	   of	   different	   diseases	   and	  dentify	   possible	   biomarker	   candidates.	   All	   data	   were	   obtained	   from	   previously	   published	  articles	  and	  public	  databases.	  Results	  of	   three	  glomerular	  proteome	  studies	  were	   compiled	  and	   the	   comparison	   of	   the	   glomerular	   disease	   transcriptome	   analyses	   was	   done	   for	   six	  different	  disease	  models	  involving	  both	  rodent	  models	  and	  human	  patients.	  The	  annotations	  of	  the	  proteins	  of	  the	  three	  proteome-­‐studies	  were	  updated	  using	  Uniprot	  (www.uniprot.org)	  and	  the	  international	  protein	  index	  (IPI)	  databases	  (www.ebi.ac.uk/IPI/IPIhuman.html).	  The	  Affymetrix	   microarray	   data	   was	   updated	   with	   the	   latest	   version	   of	   NetAffx	  (http://www.affymetrix.com/analysis/index.affx).	   The	   comparative	   analyses	   were	  performed	   using	   Microsoft	   Excel.	   The	   glomerular	   proteome	   was	   compared	   with	   a	  glomerulus-­‐enriched	   transcriptome139	   to	   show	   the	   current	   state	   of	   large-­‐scale	   proteome	  analyses	   in	   glomerular	   research.	   The	   differentially	   regulated	   genes	   of	   the	   transcriptome	  analyses	   were	   compared	   with	   each	   other	   in	   order	   to	   elucidate	   the	   possible	   similarities	  between	  the	  diseases. 	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RESULTS	  AND	  DISCUSSION	  	  
Identification	  of	  endothelial	  proteins	  by	  MALDI-­‐MS	  using	  a	  compact	  disc	  
microfluidic	  system	  (Paper	  I)	  The	   goal	   in	   this	   project	  was	   to	   identify	   proteins	   of	   cultured	   endothelial	   cells	   and	   to	   test	   a	  novel	   high-­‐throughput	   technology,	   the	   CD-­‐based	   microfluidic	   system,	   used	   for	   sample	  preparation	   prior	   to	  MS.	   This	   project	   consisted	   of	   three	   parts:	   1)	   Identification	   of	   proteins	  from	  CBB-­‐stained	   gels,	   2)	   comparison	   of	   use	   of	   conventional	   C18	   ZipTips	   and	   the	   CD-­‐based	  RPC	   system	   and	   finally,	   3)	   testing	   the	   CD-­‐based	   technology	   for	   sample	   preparation	   of	   low	  concentration	  protein	  digests	  from	  Sypro	  Ruby	  stained	  gels.	  Cytosolic	   proteins	   extracted	   from	   human	   vena	   saphena	   magna	   endothelial	   cells	   were	  separated	  with	  2-­‐DE	  using	  a	  pI	  gradient	  of	  4-­‐7.	  From	  the	  total	  of	  297	  protein	  spots	  excised,	  116	  different	  proteins	  were	  identified,	  meaning	  that	  several	  of	  the	  proteins	  were	  represented	  by	  more	   than	   one	   spot.	   Many	   of	   the	   proteins	   identified	   had	   been	   reported	   before,	   but	   we	  could	   identify	   several	   interesting	   previously	   unreported	   proteins.	   Eukaryotic	   translation	  initiation	  factor	  5A	  (eIF5A)	  is	  the	  only	  cellular	  protein	  that	  contains	  the	  unusual	  amino	  acid	  hypusine,	   that	   is	   formed	  by	  a	   series	  of	  PTMs	  of	   a	   lysine	   residue.	  Eif5A	   is	   an	  mRNA-­‐binding	  protein	  and	  is	  believed	  to	  promote	  translation	  and	  the	  formation	  of	  the	  first	  peptide	  bond	  in	  protein	  synthesis141.	  The	  protein	  is	  involved	  in	  cell	  growth,	  differentiation	  and	  p53	  regulated	  apoptosis142.	   There	   are	   two	   different	   isoforms	   of	   eIF5A,	  which	   have	   a	   sequence	   identity	   of	  84%.	  EIF5A-­‐1	   is	   expressed	  equally	   in	  all	   tissues,	  but	  EIF5A-­‐2	  has	   some	   tissue	   specificity143.	  EIF5A	  has	  been	  shown	  to	  be	  up-­‐regulated	  in	  many	  cancer	  cells	  and	  angiogenesis144.	  Chen	  et	  al	  showed	   that	   lung	   adenocarcinoma	   patients	   with	   elevated	   levels	   of	   eIF5A	   have	   decreased	  survival	   tendency145.	   Therefore	   EIF5A	   could	   be	   used	   as	   a	   prognostic	   marker	   of	   certain	  cancers.	  Forty-­‐eight	   of	   the	   297	   proteins	  were	   selected	   for	   the	   comparison	   analysis	   between	   the	   C18	  ZipTips	   and	   the	   RPC	   in	   the	   CD-­‐based	   system.	   Sequence	   coverage	   between	   three	   different	  experiments	   (manual	   ZipTiping,	  MassPrep	   station	   ZipTiping,	   duplicate	   samples	   for	   the	   CD-­‐based	  method	  to	  control	  the	  reproducibility)	  was	  combined	  and	  compared.	  	  The	  duplicates	  of	  the	  CD-­‐treated	  samples	  showed	  high	  reproducibility	  with	  a	  sequence	  coverage	  difference	  of	  8	  
± 8%.	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The	  sequence	  coverage	  was	  better	  in	  32	  of	  the	  spots	  prepared	  with	  the	  CD-­‐based	  technology,	  whereas	   in	   7	   samples	   the	   ZipTips	   resulted	   in	   better	   coverage	   and	   in	   5	   cases	   the	   manual	  ZipTips	  yielded	  a	  higher	  coverage.	  Three	  proteins	  were	  not	   identified	  and	   in	  one	  spot	   there	  was	  major	   differences	   between	   the	  methods.	   Overall	   the	   differences	   between	   the	  methods	  were	   not	   that	   significant,	   but	   manual	   ZipTiping	   is	   very	   time-­‐consuming	   and	   therefore	  technologies	  to	  speed	  up	  this	  step	  are	  needed.	  	  Finally	   the	   sensitivity	   of	   the	  method	   analyzed	   by	   running	   2-­‐DE	   loaded	  with	   only	   10	   μg	   of	  protein	   and	   stained	   with	   Sypro	   Ruby	   was	   tested.	   Sixteen	   spots	   were	   excised	   and	   after	  digestion,	   prepared	   either	   with	   manual	   ZipTiping	   or	   the	   CD	   technology.	   For	   the	   CD	  preparation	   sample	   volumes	   of	   1	   μL,	   5	   μL	   and	   10	   μL	  were	   used.	   The	   CD	   system	   yielded	   a	  result	   for	   12	   samples	   (sequence	   coverage	   ≥ 20%),	   the	   ZipTips	   only	   for	   five	   samples.	   The	  coverage	  was	   better	   in	   11	   of	   the	   samples	   prepared	  with	   the	   CD-­‐system.	   	   The	   5	   μL	   sample	  improved	  the	  sequence	  coverage	  significantly	  compared	  with	  the	  1	  μL,	  but	  the	  5	  μL	  and	  10	  μL	  experiments	  did	  not	  show	  any	  differences.	  	  Therefore	  Sypro	  Ruby	  staining	  is	  compatible	  with	  subsequent	  routine	  MS	  identification.	  	  	  
Glomerulus	  proteome	  analysis	  with	  two-­‐dimensional	  gel	  electrophoresis	  
and	  mass	  spectrometry	  (Paper	  II)	  In	  Paper	  II,	  we	  describe	  analysis	  of	  the	  proteome	  of	  healthy	  mouse	  glomeruli	  using	  2-­‐DE	  and	  MS.	  The	  purity	  of	  the	  isolated	  glomeruli	  was	  controlled	  with	  a	  light	  microscope.	  The	  glomeruli	  appeared	   to	   be	   highly	   pure	   and	   devoid	   of	   Bowman’s	   capsule.	   The	   number	   of	   glomeruli	  obtained	  from	  one	  mouse	  was	  approximately	  20,000.	  Ten	  mice	  yielded	  approximately	  1	  mg	  of	  protein.	  	  A	  total	  of	  768	  protein	  spots	  were	  excised	  from	  three	  gels:	  Two	  CBB	  stained	  gels	  with	  pI	  4-­‐7	  and	  3-­‐10	  and	  a	  silver	  stained	  gel	  with	  pI	  4-­‐7.	  The	  PMF	  analysis	  was	  performed	  with	  MALDI-­‐TOF	  MS	  for	  each	  spot,	  using	  a	  minimum	  of	  four	  matching	  peptides	  and	  sequence	  coverage	  of	  12%.	  Unidentified	  proteins	  were	  analyzed	  with	  LC-­‐MS/MS.	  A	  total	  of	  414	  protein	  spots	  could	  be	  identified,	  which	  represented	  232	  different	  proteins.	  A	  total	  of	  72	  proteins	  were	  identified	  only	  by	  silver	  staining.	  	  Most	  of	  the	  identified	  proteins	  are	  ubiquitous,	  high-­‐abundant	  housekeeping	  proteins	  whereas	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Microfluidic	  electrocapture	  for	  separation	  of	  peptides	  (Paper	  III)	  As	  mentioned	  before,	  separations	  are	  needed	  to	  reduce	  the	  complexity	  of	  biological	  samples.	  Liquid	   phase	   separation	   techniques	   are	   attractive	   because	   of	   their	   compatibility	   with	   MS	  analysis.	  The	   theoretical	  possibility	   to	   couple	   the	   liquid	  phase	   separation	   techniques	  online	  with	  MS	  is	  fascinating	  and	  important	  to	  decrease	  the	  steps	  of	  sample	  handling.	  	  In	  this	  study,	  the	  potential	  of	  the	  electrocapture	  device	  as	  a	  separation	  tool	  for	  peptides	  before	  MALDI-­‐TOF-­‐MS	   analysis	   was	   investigated.	   The	   separation	   process	   with	   the	   electrocapture	   device	   is	  described	  in	  Figure	  5.	  The	  tryptic	  peptide	  mixture	  of	  10	  proteins	  (1	  μL)	  was	  injected	  into	  the	  system	  at	   a	   flow	   rate	   of	   0.2	   μL/min,	  while	   applying	   an	   electric	   field	   of	   139	  V/cm.	   Peptides	  were	   captured	   for	   45	   min	   whereupon	   the	   electric	   field	   was	   reduced	   stepwise	   and	   each	  fraction	  analyzed	  with	  MALDI-­‐TOF-­‐MS.	  	  In	   the	   MS-­‐analysis	   we	   could	   see	   different	   profiles	   of	   peptides	   indicating	   a	   successful	  fractionation	  of	   the	  peptides.	  Positively	  charged	  peptides	  with	  pI	  9.8-­‐11.8	  were	  observed	   in	  the	  first	  fractions,	  at	  high	  electric	  field	  strengths.	  On	  the	  contrary	  negatively	  charged	  peptides	  with	  pI	   3.8-­‐7.8	  were	   eluted	   at	   lower	   electric	   field	   strengths	   (Table	  1).	   The	  prefractionation	  with	   EC	   improved	   the	   identification	   rate	   by	   14	   peptides	   compared	   with	   a	   crude	   sample	  analyzed	   with	   MS	   (Figure	   8).	   The	   ionization	   by	   MALDI	   is	   a	   competitive	   process,	   where	  molecules	   at	   high	   concentrations	   suppress	   the	   ionization	   of	   molecules	   at	   lower	  concentrations.	  In	   this	   study,	  we	   also	   explored	   the	   possibility	   to	   carry	   out	   a	   combined	   online	   cleanup	   and	  separation	  of	  a	  peptide	  mixture	  obtained	  by	  a	  shotgun	  digestion	  of	  membrane	  proteins	  of	  rat	  kidney.	  Detergents,	  such	  as	  CHAPS,	  are	  used	  to	  solubilize	  membrane	  and	  hydrophilic	  proteins.	  But	   CHAPS	   has	   to	   be	   removed	   from	   the	   peptide	   digests	   because	   it	   interferes	   with	   the	  ionization	  by	  MALDI-­‐MS.	  In	  the	  experiment,	  the	  peptide	  digest	  was	  captured	  for	  1	  h	  in	  the	  cell	  and	   washed	   extensively.	   We	   found	   that	   the	   presence	   of	   acetonitrile	   was	   critical	   for	   the	  removal	  of	  CHAPS,	  probably	  due	   to	   the	  necessity	   to	  exchange	   the	  detergent	  attached	   to	   the	  hydrophobic	  peptides	  for	  other	  molecules	  of	  low	  polarity.	  	  After	  the	  cleanup	  and	  separation,	  a	  nice	   separation	   of	   peptides	   was	   obtained.	   	   In	   this	   study	   we	   showed	   a	   novel	   strategy	   for	  peptide	   separation	   and	   online	   sample	   cleanup	   of	   a	   complex	   biological	   sample.	   This	   study	  demonstrates	   the	   great	   potential	   of	   the	   microfluidic	   technique	   for	   the	   analysis	   of	   protein	  samples.	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Table	   3.	  Molecular	   properties	   of	   the	   identified	   tryptic	   peptides	   separated	   with	   electrocapture	   and	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Membrane	   protein	   identifications	   by	   mass	   spectrometry	   using	  
electrocapture-­‐based	   separation	   as	   part	   of	   a	   2-­‐D	   fractionation	   system	  
(Paper	  IV)	  In	  the	  previous	  paper,	  the	  EC	  device	  was	  shown	  to	  be	  applicaple	  for	  the	  separation	  of	  complex	  mixtures	  of	  peptides.	  In	  this	  study,	  we	  tested	  whether	  the	  EC	  system	  could	  also	  be	  integrated	  into	   a	   2-­‐D	   system.	  We,	   therefore,	   designed	   such	   a	   two-­‐dimensional	   liquid-­‐phase	   separation	  technique	  possible	  to	  use	  for	  membrane	  protein	  identification	  by	  mass	  spectrometry.	  The	  first	  dimension	   involved	   the	  separation	  of	   tryptic	  peptides	  with	  EC.	  The	   fractions	  were	  collected	  and	  injected	  to	  the	  RPLC-­‐MS/MS	  system	  for	  the	  second	  dimension	  separation	  and	  analysis	  of	  the	  peptides.	  This	  method	  was	  controlled	  with	  a	  1-­‐D	  system	  of	  LC-­‐MS/MS,	   injecting	  3	  μL	  of	  membrane	  protein	  digest.	  For	  the	  2-­‐D	  system,	  4	  μL	  of	  each	  fraction	  was	  injected	  into	  the	  LC-­‐MS/MS	  system.	  The	  initial	  voltage	  of	  the	  EC	  was	  200	  V,	  the	  capture	  time	  was	  40	  min	  and	  the	  potential	  was	  reduced	  at	  steps	  of	  10	  V.	  Fractions	  were	  collected	  for	  15	  min	  and	  subsequently	  washed	  for	  15	  min	  before	  the	  next	  step.	  Most	  of	  the	  peptides	  were	  eluted	  between	  the	  first	  (200	  V)	  and	  fourth	  (160	  V)	  fractions	  (Table	  2).	  74	  %	  of	  the	  peptides	  were	  eluted	  in	  a	  single	  fraction	  and	  17%	  were	  eluted	  in	  the	  adjacent	  fractions	  (Table	  3).	  Most	  of	  the	  peptides,	  which	  were	  eluted	  in	  more	  than	  one	  fraction,	  were	  present	  in	  higher	  concentrations.	  We	  could	  see	  in	  the	  MS	  spectrum	  that	  the	  signal	  intensity	  of	  the	  peptide	  was	  higher	  in	  one	  fraction	  and	  lower	  in	  adjacent	  fractions	  (Figure	  9),	  an	  effect	  that	  can	   be	   seen	   in	   ion	   exchange	   or	   RPLC153.	   There	   were	   also	   differences	   between	   the	  physicochemical	   properties	   i.e.	   the	   titration	   curves	   of	   peptides	   between	   different	   fractions.	  Titration	   curves	   provide	   useful	   information	   about	   the	   electrophoretic	   properties	   of	   the	  peptides	   present	   in	   the	   EC	   fractions.	   The	   electrophoretic	   properties	   can	   be	   translated	   to	   a	  parameter	  predicting	  the	  elution	  voltage	  for	  a	  particular	  peptide	  and	  therefore	  contribute	  to	  the	   validation	   of	   the	   MS/MS-­‐predicted	   sequences.	   During	   EC-­‐based	   separations,	   peptides	  elute	   when	   the	   electrophoretic	   velocity	   is	   smaller	   than	   the	   velocity	   of	   the	   flow.	   The	  electrophoretic	  velocity	  can	  be	  formulated	  Ve	  =	  μ	  x	  E,	  where	  μ	  is	  electrophoretic	  mobility	  and	  E	  is	  the	  potential	  of	  the	  electric	  field.	  In	  addition,	  μ	  is	  directly	  related	  to	  q/M2/3,	  where	  q	  is	  the	  charge	  and	  M	  is	  the	  molecular	  weight	  of	  the	  peptide154.	  Theoretically,	  this	  means	  that	  peptides	  with	  larger	  q/M2/3	  will	  be	  eluted	  at	  lower	  electric	  fields	  and	  vice	  versa.	  This	  value	  could	  thus	  serve	  as	  a	  novel	  parameter	  to	  verify	  the	  sequence	  retrieved	  from	  the	  MS/MS	  database	  search.	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Figure	  9.	  RPLC-­‐MS	  spectra	  of	  peptides	  derived	  from	  1-­‐D	  and	  2-­‐D	  separations.	  The	  prefractionation	  of	  the	  complex	  peptide	  mixture	  with	  the	  electrocapture,	  improves	  significantly	  the	  detection	  of	  peptides.	  	  The	  peptide	  sample	  analyzed	  only	  with	  the	  LC-­‐MS/MS	  system	  resulted	  in	  the	  detection	  of	  129	  peptides.	  With	  the	  2-­‐D	  approach	  of	  EC	  and	  LC-­‐MS/MS,	  we	  could	  identify	  322	  peptides.	  It	  was	  interesting	  to	  see	  that	  240	  of	  the	  peptides	  were	  only	  identified	  with	  the	  2-­‐D	  system.	  Although	  there	  are	  clear	  advantages	  of	  coupling	  an	  EC-­‐based	  separation	  prior	  to	  an	  LC	  separation,	  some	  peptides	  were	  observed	  and	  sequenced	  only	  in	  the	  unfractionated	  sample.	  A	  similar	  effect	  has	  been	   reported	   for	   the	   combination	   of	   ion-­‐exchange	   and	   RP-­‐LC155.	   Taking	   these	   points	   into	  account,	   it	   is	  not	   surprising	   that	   the	  highest	  number	  of	   identified	  proteins	  was	  obtained	  by	  combining	  all	  of	  the	  identified	  peptides	  form	  the	  1-­‐D	  and	  2-­‐D	  separations.	  This	  combination	  also	  increases	  the	  sequence	  coverage	  of	  several	  proteins.	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Table	  4.	  Distribution	  of	  peptides	  in	  electrocapture	  fractions.	  The	  overall	  distribution	  of	  all	  peptides	  detected	  by	  MS/MS	  in	  different	  electrocapture	  fractions.	  
	  	  
Table	   5.	   Cross-­‐occurrence	   of	   the	   distinct	   peptides	   between	   the	   different	   electrocapture	   fractions.	  The	  results	   showed	   that	   a	   majority	   of	   the	   identified	   peptides	   were	   identified	   from	   one	   of	   two	   EC	   fractions.	   This	  suggests	  that	  the	  EC	  technique	  has	  a	  good	  resolution	  power	  for	  the	  separation	  of	  peptides.	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Figure	   10.	   Number	   of	   peptides	   and	   proteins	   identified	   in	   the	   1-­‐D	   and	   2-­‐D	   approaches.	   2-­‐D	   separation	  technique	   using	   elecrocapture	   as	   a	   prefractionation	   increases	   the	   number	   of	   idenfied	   peptides	   and	   proteins.	  Even	   though	  many	  peptides	  were	  only	   identified	  with	   the	  1-­‐D	  approach,	   it	  did	  not	  have	  an	  effect	  on	   the	   total	  number	  of	  proteins	  identified.	  	  	  The	   differences	   in	   identification	   between	   the	   1-­‐D	   and	   2-­‐D	   approaches	   follows	   from	   three	  aspects:	  First,	  although	  some	  peptides	  were	  present	  in	  both	  samples,	  good	  MS/MS	  data	  were	  obtained	  only	   in	   the	   fractionated	   sample,	   because	   the	   signal	   intensity	   of	   the	  precursor	  was	  higher	  that	  that	   in	  the	  unfractionated	  sample	  (Figure	  9).	  Second,	  peptides	  were	  observed	  in	  both	   samples	   and	   with	   the	   same	   intensity	   but	   were	   not	   selected	   for	   MS/MS	   because	   of	  oversampling.	   Third,	   some	  peptides	  were	   observed	   and	   sequenced	   only	   in	   the	   fractionated	  sample.	  	  As	   a	   conclusion,	   EC-­‐based	   fractionation	   system	   can	   be	   used	   as	   a	   prefractionation	   method	  prior	  to	  an	  LC-­‐MS/MS	  system	  to	  increase	  the	  detection	  rate	  of	  peptides	  in	  a	  complex	  mixture.	  The	  2-­‐D	  approach	  increases	  the	  coverage	  and	  the	  number	  of	  proteins	  identified.	  In	  addition,	  it	  removed	  considerable	  amount	  of	  detergent	  to	  improve	  the	  MS	  performance.	  Improvements	  to	  this	  2-­‐D	  approach	  are	  envisioned	  by	  means	  of	  an	  online	  connection	  of	  the	  EC	  separation	  with	  the	   LC-­‐MS/MS	   step.	   This	   will	   decrease	   the	   handling	   of	   the	   sample	   and	   sample	   losses.	   In	  conclusion,	   this	   work	   demonstrates	   that	   microfluidic	   devices	   integrated	   into	   standard	  proteomic	  technologies	  can	  be	  used	  to	  facilitate	  the	  analysis	  of	  biological	  samples.	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Expression	   pathways	   and	   networks	   in	   glomerular	   disease	   –	   a	   meta-­‐
analysis	  (Paper	  V)	  The	   aim	  of	   this	   study	  was	   to	   compile	   all	   reported	   glomerular	   proteome	   and	   transcriptome	  analyses	   in	   order	   to	   obtain	   a	   comprehensive	   picture	   of	   field.	   Such	   an	   analysis	   allows	  comparison	  of	  expression	  signatures,	  both	  protein	  and	   transcriptome	  expression,	  of	  normal	  glomeruli	   and	   in	   animal	   models	   and	   human	   disease,	   and	   thus	   insight	   into	   mechanistic	  pathways	  and	  possible	  biomarker	  candidates.	  	  	  
Proteome	  analysis	  From	  the	  PubMed	  database,	  a	  total	  of	  five	  glomerular	  proteome	  studies	  were	  found	  where	  the	  number	  of	  identified	  proteins	  was	  over	  100.	  All	  the	  studies	  involved	  healthy	  glomeruli.	  Two	  of	  the	   studies	  were	  performed	  by	  our	   laboratory156,157,	   two	  by	  a	   Japanese	  group146,152	   and	   the	  fifth	  by	  Mathias	  Mann’s	  group158.	  The	  Japanese	  group	  had	  studied	  human	  glomeruli,	  the	  rest	  of	  the	  studies	  were	  performed	  on	  mouse	  glomeruli.	   	  Tryggvason	  et	  al157	  and	  Yoshida	  et	  al146	  used	  a	  2-­‐DE	  MALDI-­‐MS	  approach	  and	  could	  identify	  over	  200	  distinct	  protein	  in	  their	  studies.	  Both	  studies	  were	  performed	  in	  or	  around	  2005	  ,	  Yoshida	  et	  al	  	  published	  their	  data	  in	  2005,	  we	   reported	   our	   results	   in	   2007,	   but	   had	   initiated	   our	   studies	   in	   2004..	   Miyamoto	   et	   al152	  reported	   later	  a	  study	  where	   they	  could	   identify	  6,686	  proteins,	   representing	  2,713	  distinct	  genes	  using	  an	  in-­‐solution	  phase	  isoelectric	  focusing	  as	  a	  prefractionation	  method	  combined	  with	  LC-­‐MS/MS.	  All	  of	  the	  proteins	  identified	  by	  Yoshida	  et	  al	  were	  identified	  by	  Miyamoto	  et	  al.	  Waanders	  et	  al158	  could	  identify	  over	  2,500	  distinct	  proteins	  in	  2009	  from	  only	  50	  mouse	  glomeruli	  using	  a	  LC-­‐MS/MS	  system.	  So	  far,	  there	  are	  not	  any	  reported	  glomerular	  proteome	  studies	  on	  glomerular	  diseases.	  The	  increase	  in	  number	  of	  identified	  proteins	  shows	  that	  the	  proteomics	   undergoes	   rapid	   development.	   However,	   it	   should	   be	   emphasized	   that	   older	  methods	   should	   not	   be	   forgotten,	   on	   the	   contrary	   the	   different	   approaches	   complemented	  each	  other.	  	  In	  the	  five	  glomerular	  studies	  (S1),	  a	  total	  of	  3,993	  proteins	  representing	  distinct	  genes	  were	  identified	  (Figure	  11).	  The	  study	  by	  Yoshida	  et	  al	  is	  not	  represented	  in	  Figure	  11,	  because	  all	  of	   the	   proteins	   identified	   in	   that	   study	  were	   also	   identified	   by	   the	   same	   group	   later	   in	   the	  study	   by	   Miyamoto	   et	   al152.	   The	   subcellular	   location	   analysis	   (S2)	   according	   to	   the	   GO	  annotation	   revealed	   that	   approximately	   50%	  of	   the	   proteins	   so	   far	   identified	   are	   cytosolic.	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Membrane	   proteins	   represent	   20%	   of	   the	   proteins.	   Cytosolic	   proteins	   are	   usually	   more	  abundant	  and	  hydrophilic,	  thus	  more	  suitable	  for	  proteomic	  analysis.	  Large	  and	  low	  abundant	  membrane	   proteins	   identified	   presents	   only	   a	   small	   percentage	   of	   the	   total	   number.	   The	  proteome	  of	  a	  cell	  is	  believed	  to	  contain	  tens	  of	  thousands	  of	  proteins	  -­‐	  this	  applies	  also	  to	  the	  glomerulus.	  Thus,	  the	  total	  number	  of	  hitherto	  identified	  glomerular	  proteins	  represents	  only	  a	  proportion	  of	  the	  glomerular	  proteome.	  	  Of	  the	  3,993	  glomerular	  proteins	   identified	  by	  MS,	  436	  (11%)	  are	  glomerulus-­‐specific	  when	  compared	  with	  the	  list	  of	  glomerular-­‐enriched	  proteins	  according	  He	  et	  al	  139,	  corresponding	  to	   30%	   of	   the	   total	   number	   of	   1,407	   highly	   glomerulus-­‐specific	   genes.	   A	   commercial	  Affymetrix	   Mouse	   Genome	   2.0	   Array	   (microarray	   chip)	   contains	   1,218	   (87%	   glomerulus-­‐enriched	  genes).	  This	  clearly	   indicates	   that	   the	  conventional	   large-­‐scale	  proteomic	   tools	  are	  still	  not	  as	  sensitive	  as	   transcriptome	  tools	   to	  study	  glomerular	  disease.	  The	   low	  number	  of	  glomerular	   protein	   identifications	   is	   mainly	   due	   to	   the	   complexity	   of	   samples	   and	   sample	  preparation,	   and	   the	   technical	   sensitivity	   issues,	   which	   are	   affected	   by	   the	   large	   dynamic	  range	  of	  protein	  concentrations.	  However,	  new	  methods	  and	  technologies	  to	  deal	  with	  these	  problems	   are	   emerging	   rapidly,	   which	   raises	   hopes	   that	   protein	   profiles	   complementing	  transcriptome	  profiles	  will	   soon	   be	   available	   and	  more	   importantly	   give	   information	   about	  the	  possible	  PTMs	  of	  the	  proteins	  involved	  in	  glomerular	  diseases.	  	  
Transcriptome	  analysis	  Glomerulus	  enriched	  transcriptome	  expression	  profiles	  have	  thus	  far	  only	  been	  reported	  for	  a	  few	   mouse	   or	   human	   glomerular	   disorders:	   (i)	   Reversible	   murine	   LPS-­‐induced	   nephrosis	  analyzed	   24	   h	   after	   administration	   of	   LPS159;	   (ii)	   Lupus	   nephritis	  mice160;	   (iii)	   Irreversible	  murine	  Adriamycin	   (ADR)	   -­‐induced	  nephrosis,	  a	  model	   for	  FSGS,	  analyzed	  4,	  7	  and	  14	  days	  after	  induction	  of	  glomerular	  injury161;	  (iv)	  Murine	  db/db	  mice,	  a	  spontaneous	  model	  for	  type	  2	   diabetes	   and	   nephropathy,	   analyzed	   2	   and	   6	   months	   after	   birth162;	   (v)	   Human	   diabetic	  nephropathy	  (DN)163	  and;	  (vi)	  Human	  glomerular	  FSGS	  and	  minimal	  change	  disease	  (MCD)164.	  Proteinuria	   is	   a	   common	   feature	   for	   all	   these	   diseases	   that	   vary	  with	   respect	   to	  molecular	  pathophysiological	  mechanisms.	  Although	  there	   is	  extensive	  variability	  between	  approaches	  and	  methodological	  procedures	  of	  most	  of	  these	  studies,	   the	  results	  provide	  support	   for	  the	  existence	  of	  a	  variety	  of	  molecular	  mechanisms	  one	  can	  visualize	  by	  expression	  profiling	  and	  that	  may	  have	  potential	  for	  development	  of	  novel	  diagnostic	  methods	  for	  glomerular	  disease.	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The	   transcriptomes	   of	   the	   seven	   disease	   models	   included	   a	   total	   of	   3,966	   differentially	  expressed	  genes	  of	  which	  3,362	  (85%)	  were	  differentially	  expressed	  in	  one	  disease	  only.	  This	  indicates	   a	   marked	   difference	   in	   gene	   expression	   in	   the	   different	   glomerular	   disease.	   The	  main	  problem	  with	  this	  kind	  of	  comparison	  is	   the	   low	  number	  of	   individual	  studies	  and	  the	  diversity	  of	  the	  disease	  and	  its	  stages	  of	  progression.	  Genes	  up-­‐	  and	  downregulated	  in	  most	  of	  the	  diseases	  are	  showed	  in	  Figure	  12.	  Many	  of	  the	  down-­‐regulated	  genes	  that	  were	  involved	  in	   more	   than	   four	   diseases	   were	   glomerulus-­‐specific.	   NEBL	   (nebulette),	   an	   actin	   binding	  protein	   involved	   in	  the	  organization	  of	   the	  cytoskeletal	  actin	   filament	  network	  and	  THSD7A	  (thrombospondin	  type	  I,	  domain	  7A)	  were	  downregulated	  in	  five	  diseases.	  The	  lack	  of	  NEBL	  might	   reflect	   irreversible	   disruption	   of	   podocin	   actin	   cytoskeleton.	   Endothelial	   THSD7A	  interacts	  with	   extracellular	   laminin,	   fibronectin,	   fibrinogen	   and	   type	   IV	   collagen	   suggesting	  that	  the	  endothelium	  is	  also	  intact	  and	  the	  organization	  between	  the	  mesangium	  and	  capillary	  tufts	   is	   disruptured.	   NEBL	   and	   THSD7A	   are	   thus	   downregulated	   in	   both	   acute	   and	   chronic	  disease.	   These	   genes	   or	   proteins	   are	   not	   well	   studied,	   were	   not	   linked	   to	   any	   canonical	  pathway	   in	   IPA,	   and	   are	   involved	   in	   only	   few	   interactions	   according	   to	   the	   Ingenuity	  Knowledgebase	  or	   the	  Human	  Protein	  Reference	  Database.	  These	  genes/proteins	  should	  be	  studied	  more	  closely	  as	  they	  might	  be	  potential	  biomarker	  candidates	  for	  acute	  and	  chronic	  kidney	  injury.	  These	  findings	  also	  imply	  that	  basic	  research	  is	  still	  needed	  to	  gain	  more	  basic	  information	   about	   the	   functions	   and	   interactions	   of	   separate	   genes	   and	  proteins	   to	   be	   able	  perform	  informative	  systems	  biology	  analyses.	  	  Most	  of	  the	  genes	  upregulated	  in	  the	  disease	  models	  play	  roles	  in	  cell	  growth,	  apoptosis	  and	  inflammation.	  This	  correlates	  well	  with	  the	  notion	  that	  constant	  inflammation	  and	  structural	  changes	  in	  the	  glomeruli	  lead	  to	  sclerosis	  in	  CKD165.	  CDKN1A,	  which	  encodes	  cyclin	  dependent	  kinase	  inhibitor	  A,	  is	  the	  only	  glomerulus	  specific	  gene,	  which	  is	  upregulated	  in	  at	   least	  four	  disease	  models.	   	  CDKN1A	  is	  an	  acute	  phase	  protein,	  which	  promotes	  apoptosis	  during	  acute	  kidney	   injury.	   Closer	   study	   of	   CDKN1A	   related	   pathways	   and	   networks	  might	   reveal	   novel	  knowledge	  of	  the	  initial	  pathomechanisms	  of	  different	  glomerular	  diseases.	  	  	  
Pathway	  and	  network	  analysis	  in	  glomerular	  disease	  Global	  expression	  analyses	  and	  tools	  such	  as	  IPA	  enable	  us	  to	  visualize	  the	  results	  and	  show	  which	   canonical	   molecular	   pathways	   and	   networks	   that	   are	   active	   at	   different	   stages	   of	  disease	   progression	   and	   recovery.	   	   Canonical	   pathways	   and	   functional	   networks	   for	   the	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differentially	   expressed	   genes	   in	   the	   disease	  models	  were	   compared	  with	   IPA	   (S5-­‐S8).	   The	  diseases	   compared	   in	   this	   meta-­‐analysis	   have	   different	   etiology,	   are	   at	   different	   stages	   of	  progression,	  have	  different	  pathophysiological	  mechanisms,	  and	  have	  different	  morphological	  changes	  in	  the	  glomeruli.	  This	  can	  be	  seen	  also	  in	  the	  comparisons	  of	  pathways	  and	  networks	  that	  are	  affected	  in	  the	  disease	  models.	  Clearly,	  one	  can	  state	  that	  inflammation	  and	  fibrosis	  responses	   are	   common	   to	   all	   disease	   models,	   but	   the	   important	   items	   to	   know	   are	   the	  pathways	   involved	   in	   the	  triggering	  and	  early	  stages	  of	   the	  disease.	  With	  the	  available	  data,	  more	  detailed	  comparisons	  of	  all	  the	  disease	  models	  at	  the	  same	  time	  is	  not	  possible	  due	  to	  the	  different	  nature	  of	  etiology,	  stages	  of	  the	  diseases,	  and	  low	  number	  of	  individuals	  studied.	  	  The	   db/db	   mouse	   is	   a	   well-­‐established	   model	   to	   study	   diabetic	   nephropathy.	   There	   was	  therefore	   a	   particular	   interest	   to	   compare	   the	   expression	   profiles	   in	   human	   diabetic	  nephropathy	  and	  db/db	  mice,	  as	  diabetic	  nephropathy	  is	  the	  commonest	  cause	  of	  human	  end-­‐stage	  renal	  disease,	  and	  whether	  db/db	  mice	  serve	  as	  a	  good	  model	  for	  type	  2	  diabetes.	  At	  2	  months	   of	   age,	   eighty	   percent	   of	   the	   differentially	   expressed	   genes	   were	   upregulated.	   The	  db/db	  mice	  exhibited	  acute	  inflammatory	  signs	  in	  the	  glomeruli	  and	  development	  of	  fibrosis	  and	   angiogenesis	   signaling.	   At	   age	   6	   months,	   which	   closely	   resembles	   clinical	   stage	   3	   of	  diabetic	   nephropathy	   in	   humans,	   the	   acute	   inflammation	   has	   subdued.	   However	   an	   innate	  immune	  response	  prevails	  in	  the	  db/db	  mice,	  and	  the	  sugar	  metabolism	  pathways	  are	  down-­‐regulated,	   which	   suggests	   that	   the	   ability	   to	   metabolize	   sugar	   is	   diminishing.	   Sixty	   three	  percent	  of	  the	  differentially	  expressed	  genes	  were	  still	  upregulated.	  Woroniecka	  et	  al163	  did	  a	  transcriptome	   study	   for	   type	   2	   diabetes	   nephropathy	   patients	  with	   stage	   3-­‐4	   nephropathy,	  showing	  proteinuria	  and	  advanced	  glomerulosclerosis.	  Only	  thirty	  percent	  of	  the	  differentially	  expressed	  genes	  were	  upregulated.	  Pathway	  analysis	  showed	  a	  decrease	  in	  integrin	  and	  actin	  cytoskeleton	  signaling,	  and	  an	   increase	   in	   leukocyte	  extravasation	  and	   fibrosis.	   	  At	   the	  gene	  level,	  only	  19	  genes	  were	  similarly	  expressed	  between	  db/db	  mouse	  glomeruli	  at	  6	  months	  and	  the	  human	  DN	  glomeruli.	   	   IPA	  did	  not	  match	  these	  genes	  to	  any	  reasonable	  pathway	  or	  network.	   Despite	   the	   differences	   between	   the	   transcriptomes	   of	   db/db	   and	   human	   DN	  glomeruli,	   we	   still	   cannot	   state	   that	   the	   db/db	   mouse	   is	   not	   a	   good	   model	   for	   diabetic	  nephropathy.	   This	   was	   the	   first	   time	   a	   comparison	   was	   made	   between	   gene	   expression	  patterns	   conducted	   in	   different	   laboratories.	   The	   high	   p-­‐values	   in	   the	   data	   of	   6-­‐month-­‐old	  db/db	  mice	  indicate	  significant	  differences	  between	  the	  individual	  mice.	  It	  may	  also	  be	  so	  that	  the	  stages	  of	  mice	  and	  human	  do	  not	  match.	  Recently,	  Hudkins	  et	  al	  reported	  that	  BTBR	  ob/ob	  mice	   develop	   a	   rapidly	   progressive	   diabetic	   nephropathy	   more	   similar	   to	   the	   clinical	   and	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morphological	   changes	   found	   in	   humans166.	   There	   is	   however	   no	   glomerular	   expression	  pattern	  published	  from	  that	  model	  yet.	  Expression	   patterns,	   pathway	   and	   network	   analyses	   are	   more	   suitable	   for	   the	   analysis	   of	  disease	  progression.	  During	  the	  progression	  of	  a	  disease,	  the	  cells	  undergo	  a	  series	  of	  stages.	  Each	   stage	   in	   the	   cell	   can	   be	   associated	  with	   a	   specific	   transcriptome	   or	   proteome	   profile.	  With	  a	  detailed	  analysis	  of	  the	  transcriptome	  or	  proteome	  expression	  changes	  during	  disease	  progression,	  the	  pathomechanical	  pathways	  and	  networks	  can	  be	  determined.	  With	  the	  help	  of	   expression	   profile	   databases,	   one	   may	   then	   be	   able	   to	   accurately	   identify	   the	   disease	  profiles	  of	  patients,	  determine	  the	  progression	  status	  of	  the	  disease	  and	  assign	  a	  personalized	  therapy	   for	   patients.	   This	   will	   of	   course	   need	   extensive	   expression	   databases	   and	   the	  knowledge	  of	   the	  pathomechanisms	  of	   the	  disease.	  The	  expression	  profiles	  may	  not	  only	  be	  used	   to	   study	   the	   progression	   of	   the	   disease,	   but	   also	   follow	  up	   and	  monitor	   the	   effects	   of	  therapies	   and	   the	   recover	   process.	   Figure	   13	   illustrates	   the	   concept	   of	   expression	  profiling	  during	  disease	  progression.	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Figure	   13.	   Illustration	   of	   transcriptome	   profile	   clustering	   during	   disease	   progression	   in	   ADR-­‐induced	  
nephrosis.	   	   The	   glomerular	   transcriptome	   was	   analyzed	   at	   three	   different	   time	   points	   during	   disease	  progression	   of	   Adriamycin-­‐induced	   nephrosis	   in	  mice161.	   Day	   0,	   prior	   to	   administration	   of	   ADR,	   day	   4,	   when	  proteinuria	   had	   developed	   but	   abnormal	   histology	   was	   not	   apparent	   by	   light	   microscopy,	   day	   7,	   when	  proteinuria	  was	  at	  maximum	  and	  electron	  microscopy	  revealed	   foot	  process	  effacement	  without	  GBM	  changes	  and	  day	  14,	  when	  the	  proteinuria	  had	  diminished,	  but	  histological	  analyses	  showed	  FSGS	  changes	  in	  about	  5-­‐8%	  of	   the	   glomeruli.	   Such	   expression	   signatures	   could	   be	   important	   and	   useful	   for	   the	   development	   of	   new	  diagnostic	  methods	   identifying	  molecular	  pathways	  and	  expression	   signatures	   for	  different	   types	  of	   early	   and	  advanced	  glomerular	  disease.	  	  	  The	   analysis	  methods	   and	   graphics	   for	   visualizing	   the	   results	   are	   still	   too	   complicated	   for	  routine	   clinical	   nephrology,	   but	   the	   development	   of	   software	   is	   rapid	   and	   the	   procedures	  become	  more	  and	  more	  user-­‐friendly	  and	  clear.	  The	  analysis	  of	  transcriptome	  and	  proteome	  profiling	  actually	  apply	  better	  to	  glomeruli	   than	  to	  samples	   from	  many	  other	  tissues	  due	  to	  the	  easy	  access	  of	  pure	  glomeruli.	  We	  are	  also	  convinced	  that	  global	  gene	  expression	  profiles	  of	   isolated	   glomeruli	   will	   make	   a	   significant	   impact	   on	   future	   diagnosis	   and	   therapy	   of	  glomerular	  disease.	  The	  currently	  available	  research	  results	  on	  glomerular	  RNA	  and	  protein	  expression	  profiling	  are	  amazingly	  limited	  in	  number,	  but	  this	  is	  likely	  to	  change	  in	  the	  near	  future.	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GENERAL	  CONCLUSIONS	  AND	  FUTURE	  PERSPECTIVES	  Proteomic	   analyses	   include	   a	   wide	   variety	   of	   methods	   in	   many	   areas	   of	   applications.	   The	  selection	  of	  methods	  is	  of	  great	  importance	  for	  the	  outcome	  of	  a	  proteomic	  study.	  Large-­‐scale	  proteome	   analyses	   require	   analytical	   tools,	   which	   can	   handle	   complex	   protein	  mixtures	   of	  tens	  of	  thousands	  of	  proteins.	  	  Two-­‐dimensional	  gel	  electrophoresis	  is	  a	  widely	  used	  separation	  method	  of	  complex	  protein	  mixtures.	   The	   method	   can	   separate	   thousands	   of	   proteins,	   is	   highly	   reproducible	   and	   can	  readily	   distinguish	   different	   PTMs.	   However,	   the	   drawbacks	   of	   2-­‐DE	   have	   facilitated	   the	  development	   of	   proteomics	   towards	  MS-­‐based	   proteomics.	   2-­‐DE-­‐based	   proteomics	   is	   quite	  complex	  and	  includes	  a	  lot	  of	  sample	  handling	  and	  steps	  before	  MS	  analysis	  of	  protein	  digests.	  Technological	  automation	  such	  as	  the	  microfluidic	  CD-­‐based	  system	  for	  sample	  cleanup	  and	  concentration	  were	   needed	   to	   speed	   up	   the	   process	  maintaining	   sensitivity.	   The	   CD-­‐based	  system	  was	  found	  to	  be	  reproducible,	  fast	  and	  sensitive	  and	  could	  replace	  the	  manual	  step	  of	  desalting	   and	   sample	   application	   to	   a	   MALDI	   target	   plate.	   The	   identification	   of	   mouse	  glomerulus	  proteins	  by	  2-­‐DE	  provided	  some	  new	  knowledge	  about	  the	  glomerular	  proteome	  even	  though	  the	  number	  of	  identified	  proteins	  remained	  quite	  low.	  To	  overcome	  the	  need	  of	  extensive	  sample	  handling	   in	  2-­‐DE,	  new	  technologies	  are	  developed,	  especially	   liquid	  phase	  microfluidic	   systems,	   which	   could	   be	   coupled	   directly	   with	   ESI-­‐MS.	   The	   electrocapture	  technology	   is	   a	   relatively	   young	   technology,	   but	   has	   further	   promise.	   It	   is	   based	   on	   the	  capability	   to	  capture	  charged	  molecules	   in	  a	  hydrodynamic	   flow	  under	  an	  electric	   field.	  The	  device	  could	  perform	  several	  proteomic	  applications	  such	  as	  sample	  concentration,	  cleanup,	  reduction	  and	  alkylation	  of	  proteins.	   In	   this	   thesis,	  we	  showed	  that	   the	   technology	  could	  be	  used	   to	   separate	   peptide	   or	   protein	   mixtures	   and	   that	   the	   device	   could	   be	   used	   as	   a	  prefractionation	  method	  to	  identify	  glomerular	  membrane	  bound	  proteins	  with	  an	  LC-­‐MS/MS	  system.	  	  Proteomics	  have	  developed	  much	  during	  the	  time	  of	  my	  PhD	  studies.	  The	  focus	  in	  proteomic	  has	   changed	   from	   small-­‐scale	   projects	   towards	   large-­‐scale	   studies	   and	   from	   qualitative	  expression	   patterns	   towards	   dynamics	   and	   turnover	   in	   different	   cell	   types	   and	   under	  different	  conditions.	  The	  emphasis	  is	  on	  the	  study	  of	  the	  global	  patterns	  in	  a	  cell,	  tissue	  or	  an	  organism,	  such	  as	  protein-­‐protein	   interactions	  and	  protein-­‐nucleotide	   interaction	  networks,	  metabolic	  pathways,	  signaling	  cascades	  networks,	  and	  gene	  and	  protein	  expression	  patterns.	  Even	   though	   proteomic	   tools	   and	   approaches	   have	   developed	   much,	   proteomic	   tools	   still	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